Status,Conditions,Interventions,Sponsor/Collaborators,Enrollment,Study Designs,Start Date,Results First Posted,Locations,URL
Completed,Rheumatoid Arthritis,Drug: SARILUMAB|Drug: Azathioprine|Drug: Chloroquine|Drug: Hydroxychloroquine|Drug: Leflunomide|Drug: Methotrexate|Drug: Sulfasalazine,Sanofi|Regeneron Pharmaceuticals,84,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5-Mar-18,10-Aug-20,"Investigational Site Number 250007, Argenteuil, France|Investigational Site Number 250006, Besancon, France|Investigational Site Number 250027, Bobigny, France|Investigational Site Number 250016, Bordeaux, France|Investigational Site Number 250014, Caen, France|Investigational Site Number 250032, CAHORS Cedex 9, France|Investigational Site Number 250019, Cannes, France|Investigational Site Number 250013, Cholet, France|Investigational Site Number 250002, Clermont Ferrand, France|Investigational Site Number 250009, Echirolles, France|Investigational Site Number 250005, La Roche Sur Yon, France|Investigational Site Number 250024, Le Mans Cedex 9, France|Investigational Site Number 250004, Lille Cedex, France|Investigational Site Number 250012, Limoges Cedex, France|Investigational Site Number 250021, Lyon, France|Investigational Site Number 250018, Montivilliers, France|Investigational Site Number 250029, MONTPELLIER Cedex 5, France|Investigational Site Number 250025, NANTES Cedex 1, France|Investigational Site Number 250026, Nice cedex 1, France|Investigational Site Number 250020, Paris Cedex 10, France|Investigational Site Number 250011, PARIS Cedex 13, France|Investigational Site Number 250010, Paris, France|Investigational Site Number 250015, Paris, France|Investigational Site Number 250028, Paris, France|Investigational Site Number 250033, Paris, France|Investigational Site Number 250031, Poitiers, France|Investigational Site Number 250023, Pontoise, France|Investigational Site Number 250017, RENNES Cedex, France|Investigational Site Number 250008, Rouen, France|Investigational Site Number 250001, St Etienne, France|Investigational Site Number 250034, Strasbourg Cedex 2, France|Investigational Site Number 250022, Toulouse, France|Investigational Site Number 250003, Tours, France",https://ClinicalTrials.gov/show/NCT03449758
Terminated,Heart Failure,Drug: Bisoprolol,"Merck KGaA, Darmstadt, Germany|Merck Serono Co., Ltd., China",20,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,21-Mar-17,29-Jan-20,"Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, China",https://ClinicalTrials.gov/show/NCT03026088
Terminated,Non-obstructive Coronary Artery Disease,Drug: Nicorandil,"Merck KGaA, Darmstadt, Germany|Merck Serono Co., Ltd., China",8,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30-Nov-16,7-Jul-20,"Peking union medical college hospital, Beijing, China",https://ClinicalTrials.gov/show/NCT03010423
Completed,Macular Degeneration,"Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)",Bayer|Regeneron Pharmaceuticals,287,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-Nov-15,21-May-20,"Strathfield, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|East Melbourne, Victoria, Australia|Launceston, Australia|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Boisbriand, Quebec, Canada|Creteil Cedex, France|Nice cedex 1, France|Freiburg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Hannover, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Sulzbach, Saarland, Germany|Chemnitz, Sachsen, Germany|Berlin, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Szombathely, Hungary|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Padova, Veneto, Italy|Oviedo, Asturias, Spain|Madrid, Spain|Zaragoza, Spain|Canterbury, Kent, United Kingdom|Bristol, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT02581891
Completed,Allergic Conjunctivitis,Drug: Refresh Tears 0.5% Lubricant Eye Drops|Drug: Bepreve 1.5% Ophthalmic Solution,"Minnesota Eye Consultants, P.A.|Bausch & Lomb Incorporated",40,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,May-11,31-Mar-20,"Minnesota Eye Consultants, P.A., Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT01346371
Completed,Acute Coronary Syndromes,Drug: Apixaban|Drug: vitamin K antagonist|Drug: Acetylsalicylic acid|Other: Acetylsalicylic acid placebo,Bristol-Myers Squibb|Pfizer|Duke Clinical Research Institute,4614,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Other,4-Jun-15,7-Feb-20,"Cardiovascular Associates of the Southeast, LLC, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Heart Rhythm Center, Phoenix, Arizona, United States|Local Institution, Phoenix, Arizona, United States|Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States|Southern Arizona VA Health Care System, Tucson, Arizona, United States|Local Institution, Little Rock, Arkansas, United States|Local Institution, Phoenix, Arkansas, United States|Comprehensive Cardiovascular Specialists, Alhambra, California, United States|Local Institution, Culver City, California, United States|Washington Township Medical Foundation, Fremont, California, United States|California Heart Specialist, Inc., Huntington Beach, California, United States|Foundation For Cardiovascular Medicine, La Jolla, California, United States|Local Institution, Long Beach, California, United States|Local Institution, Rancho Mirage, California, United States|Local Institution, San Diego, California, United States|Manshadi Heart Institute, Stockton, California, United States|Local Institution, Torrance, California, United States|University Of Colorado, Aurora, Colorado, United States|Colorado Heart and Vascular, Lakewood, Colorado, United States|Local Institution, Norwalk, Connecticut, United States|Local Institution, Wilmington, Delaware, United States|Orlando Heart Specialists, Altamonte Springs, Florida, United States|Local Institution, Bradenton, Florida, United States|Clearwater Cardiovascular and Interventional Consultants, Clearwater, Florida, United States|Local Institution, Clearwater, Florida, United States|Daytona Heart Group, Daytona Beach, Florida, United States|Local Institution, Fort Lauderdale, Florida, United States|Local Institution, Jacksonville Beach, Florida, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Jacksonville, Florida, United States|Tenet Florida Physician Services, Jupiter, Florida, United States|Local Institution, Lake Mary, Florida, United States|Local Institution, Miami, Florida, United States|Mediquest Research, Ocala, Florida, United States|Local Institution, Orlando, Florida, United States|CP Cardiology Partners, Palm Beach Gardens, Florida, United States|Bayfront Health St. Petersburg, Saint Petersburg, Florida, United States|Local Institution, Tampa, Florida, United States|Cardiology Partners, Wellington, Florida, United States|Athens Regional Cariology Group, Athens, Georgia, United States|Local Institution, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Georgia Heart Specialists, Covington, Georgia, United States|Local Institution, Cumming, Georgia, United States|Local Institution, Tucker, Georgia, United States|Saint Lukes Idaho Cardiology Associates, Boise, Idaho, United States|Medicoricium, LLC, Fairview Heights, Illinois, United States|Gateway Cardiology PC, Jerseyville, Illinois, United States|Advocate Medical Group ? Cardiology and Pulmonology, Normal, Illinois, United States|South Suburban Cardiology, Olympia Fields, Illinois, United States|Local Institution, Bloomington, Indiana, United States|Elkhart Clinic LLC, Elkhart, Indiana, United States|Roudebush VA Medical Center, Indianapolis, Indiana, United States|Reid Hospital and Health Care Services, Richmond, Indiana, United States|Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States|University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States|Northeast Iowa Family Practice Center, Waterloo, Iowa, United States|Local Institution, Kansas City, Kansas, United States|Local Institution, Wichita, Kansas, United States|Saint Elizabeth Healthcare, Crestview Hills, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States|Imperial Health, Lake Charles, Louisiana, United States|Local Institution, Minden, Louisiana, United States|Clinical Trials of America LA LLC - PPDS, Monroe, Louisiana, United States|Local Institution, Natick, Massachusetts, United States|Great Lakes Heart Center of Alpena, Alpena, Michigan, United States|Local Institution, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Lansing, Michigan, United States|Covenant Center for the Heart, Saginaw, Michigan, United States|Metropolitan Cardiology Consultants, Minneapolis, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Local Institution, Jackson, Mississippi, United States|Cardiology Associates Research LLC, Tupelo, Mississippi, United States|Missouri Cardiovascular Specialists, Columbia, Missouri, United States|Local Institution, Columbia, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Gateway Cardiology PC, Saint Louis, Missouri, United States|St. Louis Heart and Vascular, Saint Louis, Missouri, United States|Cox Health Systems, Springfield, Missouri, United States|Local Institution, Billings, Montana, United States|Bryan Heart Hospital, Lincoln, Nebraska, United States|HCP Clinical Research LLC, Las Vegas, Nevada, United States|Renown Regional Medical Center., Reno, Nevada, United States|New Jersey Heart, Linden, New Jersey, United States|Capital Cardiology Associates, Albany, New York, United States|New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Local Institution, Brooklyn, New York, United States|Buffalo Heart Group LLP, Buffalo, New York, United States|Mount Sinai-St. Lukes, New York, New York, United States|Hudson Valley Cardiovascular Practice, PC, Poughkeepsie, New York, United States|Asheville Cardiology Associates PA, Asheville, North Carolina, United States|University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America-NC, LLC - PPDS, Lenoir, North Carolina, United States|Duke Cardiology and Cardiovascular Surgery of Lumberton, Lumberton, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Kettering, Ohio, United States|Local Institution, Willoughby, Ohio, United States|Saint Vincent Hospital, Erie, Pennsylvania, United States|Heart Group, Lancaster, Pennsylvania, United States|Mercer Bucks Cardiology, Newton, Pennsylvania, United States|WellSpan York Hospital, York, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Columbia Heart, Columbia, South Carolina, United States|Upstate Cardiology PA, Greenville, South Carolina, United States|Roper St. Francis Healthcare, North Charleston, South Carolina, United States|Carolina Cardiology Clinical Research Institute, Rock Hill, South Carolina, United States|Local Institution, Germantown, Tennessee, United States|Research Associates of Jackson, Jackson, Tennessee, United States|Cardiovascular Research of Knoxville, Knoxville, Tennessee, United States|Knoxville Health Managment Associates Cardiology PPM LLC, Knoxville, Tennessee, United States|Parkway Cardiology Associates PC, Oak Ridge, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|San Antonio Military Medical Center, Fort Sam Houston, Texas, United States|Angiocardiac Care of Texas PA, Houston, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Houston, Texas, United States|Grace Research, LLC, Huntsville, Texas, United States|Local Institution, Huntsville, Texas, United States|Local Institution, Katy, Texas, United States|Caprock Cardiac Center Research Institute, Lubbock, Texas, United States|Local Institution, Plano, Texas, United States|Local Institution, San Antonio, Texas, United States|Mercury Medical LLC, San Antonio, Texas, United States|Local Institution, Sealy, Texas, United States|Local Institution, Sugar Land, Texas, United States|Victoria Heart and Vascular Center, Victoria, Texas, United States|University of Vermont, Burlington, Vermont, United States|Virginia Heart, Falls Church, Virginia, United States|Virginia Heart Group Ltd, Leesburg, Virginia, United States|CJW Medical Center, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|St Mary's Medical Center, Huntington, West Virginia, United States|Aspirus Research Institute, Wausau, Wisconsin, United States|Local Institution, Buenos Aires, BUA, Argentina|Local Institution, Bahia Blanca, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Coronel Suarez, Buenos Aires, Argentina|Local Institution, Lanus Oeste, Buenos Aires, Argentina|Local Institution, Mar del Plata, Buenos Aires, Argentina|Local Institution, Mar Del Plata, Buenos Aires, Argentina|Local Institution, Quilmes, Buenos Aires, Argentina|Local Institution, Quilmes, Buenos Aires, Argentina|Local Institution, Ramos Mejia, Buenos Aires, Argentina|Local Institution, Ramos Mejia, Buenos Aires, Argentina|Local Institution, Vicente Lopez, Buenos Aires, Argentina|Local Institution, Resistencia, Chaco, Argentina|Local Institution, Ciudad De Cordoba, Cordoba, Argentina|Local Institution, Villa Allende, Cordoba, Argentina|Local Institution, Villa Maria, Cordoba, Argentina|Local Institution, Rosario, Santa FE, Argentina|Local Institution, Rosario, Santa FE, Argentina|Local Institution, Rosario, Santa FE, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Corrientes, Argentina|Local Institution, Santa Fe, Argentina|Local Institution, Santa Fe, Argentina|Local Institution, Santa Fe, Argentina|Local Institution, Santiago Del Estero, Argentina|Local Institution, Concord, New South Wales, Australia|Local Institution, Port Macquarie, New South Wales, Australia|Local Institution, Milton, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Bedford Park, Australia|Local Institution, Graz, Austria|Local Institution, Graz, Austria|Local Institution, Linz, Austria|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Aalst, Belgium|Local Institution, Antwerpen, Belgium|Local Institution, Bonheiden, Belgium|Local Institution, Brasschaat, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Ieper, Belgium|Local Institution, Leuven, Belgium|Local Institution, Wilrijk, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Colatina, Espirito Santo, Brazil|Local Institution, Aparecida de Goiania, Goias, Brazil|Local Institution, Goiania, Goias, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Uberaba, Minas Gerais, Brazil|Local Institution, Uberlandia, Minas Gerais, Brazil|Local Institution, Campina Grande Do Sul, Parana, Brazil|Local Institution, Londrina, Parana, Brazil|Local Institution, Belem, Para, Brazil|Local Institution, Recife, Pernambuco, Brazil|Local Institution, Recife, Pernambuco, Brazil|Local Institution, Canoas, RIO Grande DO SUL, Brazil|Local Institution, Passo Fundo, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Blumenau, Santa Catarina, Brazil|Local Institution, Itajai, Santa Catarina, Brazil|Local Institution, Campinas, SAO Paulo, Brazil|Local Institution, Limeira, SAO Paulo, Brazil|Local Institution, Marilia, SAO Paulo, Brazil|Local Institution, S?o Paulo, SAO Paulo, Brazil|Local Institution, S?o Paulo, SAO Paulo, Brazil|Local Institution, S?o Paulo, SAO Paulo, Brazil|Local Institution, Santo Andre, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Local Institution, Votuporanga, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Burgas, Bulgaria|Local Institution, Dimitrovgrad, Bulgaria|Local Institution, Haskovo, Bulgaria|Local Institution, Montana, Bulgaria|Local Institution, Pazardzhik, Bulgaria|Local Institution, Pleven, Bulgaria|Local Institution, Plovdiv, Bulgaria|Local Institution, Sandanski, Bulgaria|Local Institution, Smolyan, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Veliko Tarnova, Bulgaria|Local Institution, Vidin, Bulgaria|Local Institution, Edmonton, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Kelowna, British Columbia, Canada|Local Institution, New Westminster, British Columbia, Canada|Local Institution, Victoria, British Columbia, Canada|Local Institution, Winnepeg, Manitoba, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Cambridge, Ontario, Canada|Local Institution, London, Ontario, Canada|Local Institution, Oshawa, Ontario, Canada|Local Institution, Scarborough, Ontario, Canada|Local Institution, Scarborough, Ontario, Canada|Local Institution, Sudbury, Ontario, Canada|Local Institution, Sudbury, Ontario, Canada|Local Institution, Waterloo, Ontario, Canada|Local Institution, Green Field Park, Quebec, Canada|Local Institution, Laval, Quebec, Canada|Local Institution, Longueuil, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, St-Georges, Beauce, Quebec, Canada|Local Institution, St-Jean-sur-Richelieu, Quebec, Canada|Local Institution, St. Jerome, Quebec, Canada|Local Institution, Regina, Saskatchewan, Canada|Local Institution, Montreal, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Barranquilla, Colombia|Local Institution, Barranquilla, Colombia|Local Institution, Bogota, Colombia|Local Institution, Cali, Colombia|Local Institution, Espinal, Colombia|Local Institution, Medellin, Colombia|Local Institution, Cakovec, Croatia|Local Institution, Dubrovnik, Croatia|Local Institution, Karlovac, Croatia|Local Institution, Krapinske toplice, Croatia|Local Institution, Opatija, Croatia|Local Institution, Osijek, Croatia|Local Institution, Rijeka, Croatia|Local Institution, Sibenik, Croatia|Local Institution, Slavonski Brod, Croatia|Local Institution, Virovitica, Croatia|Local Institution, Zabok, Croatia|Local Institution, Zadar, Croatia|Local Institution, Zagreb, Croatia|Local Institution, Prague 8, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Praha 5, Czechia|Local Institution, Tabor, Czechia|Local Institution, Usti Nad Orlici, Czechia|Local Institution, Zlin, Czechia|Local Institution, Aabenraa, Denmark|Local Institution, Aarhus, Denmark|Local Institution, Copenhagen, Denmark|Local Institution, Frederiksburg, Denmark|Local Institution, Hellerup, Denmark|Local Institution, Hillerod, Denmark|Local Institution, Holb?k, Denmark|Local Institution, Hvidovre, Denmark|Local Institution, Randers, Denmark|Local Institution, Roskilde, Denmark|Local Institution, Slagelse, Denmark|Local Institution, Besancon, France|Local Institution, Caen, France|Local Institution, Chambray-les-Tours, France|Local Institution, Le Coudray, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Nimes, France|Local Institution, Pau, France|Local Institution, Pessac, France|Local Institution, Toulouse, France|Local Institution, Bad Friedrichshall, Germany|Local Institution, Bad Homburg, Germany|Local Institution, Bad Homburg, Germany|Local Institution, Berlin, Germany|Local Institution, Berlin, Germany|Local Institution, Berlin, Germany|Local Institution, Bielefeld, Germany|Local Institution, Brandenburg, Germany|Local Institution, Bremen, Germany|Local Institution, Chemnitz, Germany|Local Institution, Dortmund, Germany|Local Institution, Dresden, Germany|Local Institution, Dresden, Germany|Local Institution, Erfurt, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Freiburg, Germany|Local Institution, Gottingen, Germany|Local Institution, Greifswald, Germany|Local Institution, Hamburg, Germany|Local Institution, Hamburg, Germany|Local Institution, Hansestadt Stendal, Germany|Local Institution, Hennigsdorf, Germany|Local Institution, Hoyerswerda, Germany|Local Institution, Jena, Germany|Local Institution, Karlsbad, Germany|Local Institution, Kassel, Germany|Local Institution, Koln, Germany|Local Institution, Lahr, Germany|Local Institution, Leipzig, Germany|Local Institution, Limburg, Germany|Local Institution, Ludenscheid, Germany|Local Institution, Luebeck, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Neuss, Germany|Local Institution, Papenburg, Germany|Local Institution, Regensburg, Germany|Local Institution, Rostock, Germany|Local Institution, Straubing, Germany|Local Institution, Tubingen, Germany|Local Institution, Ulm, Germany|Local Institution, Villingen-Schwenningen, Germany|Local Institution, Weiden i.d.OPf., Germany|Local Institution, Worms, Germany|Local Institution, Wurzburg, Germany|Local Institution, Baja, Bacs-kiskun, Hungary|Local Institution, Bekescsaba, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Keszthely, Hungary|Local Institution, Mosonmagyarovar, Hungary|Local Institution, Pecs, Hungary|Local Institution, Pecs, Hungary|Local Institution, Szeged, Hungary|Local Institution, Szekszard, Hungary|Local Institution, Szolnok, Hungary|Local Institution, Ahmedabad, Gujarat, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Amritsar, India|Local Institution, Jaipur,, India|Local Institution, Lucknow, India|Local Institution, Madurai, India|Local Institution, Mangalore, India|Local Institution, New Delhi, India|Local Institution, New Delhi, India|Local Institution, Noida, India|Local Institution, Shivamogga, India|Local Institution, Vadodara, India|Local Institution, Vijayawada, India|Local Institution, Afula, Israel|Local Institution, Ashkelon, Israel|Local Institution, Hadera, Israel|Local Institution, Haifa, Israel|Local Institution, Haifa, Israel|Local Institution, Haifa, Israel|Local Institution, Herzliya, Israel|Local Institution, Holon, Israel|Local Institution, Jerusalem, Israel|Local Institution, Ramat-Gan, Israel|Local Institution, Rehovot, Israel|Local Institution, Safed, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Tiberias, Israel|Local Institution, Grosseto, Italy|Local Institution, Busan, Korea, Republic of|Local Institution, Changwon, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daejeon, Korea, Republic of|Local Institution, Gwang Ju, Korea, Republic of|Local Institution, Incheon, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Torreon, Coahuila, Mexico|Local Institution, Leon, Guanajuato, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, San Juan del Rio, Queretaro, Mexico|Local Institution, Queretaro, QUE, Mexico|Local Institution, Culiacan, Sinaloa, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Durango, Mexico|Local Institution, Puebla, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, Tlalnepantla De Baz, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Arnhem, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Ede, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Hardenberg, Netherlands|Local Institution, Maastricht, Netherlands|Local Institution, Nieuwegein, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Tilburg, Netherlands|Local Institution, Uden, Netherlands|Local Institution, Bod?, Norway|Local Institution, Oslo, Norway|Local Institution, Oslo, Norway|Local Institution, Skien, Norway|Local Institution, Stavanger, Norway|Local Institution, Tromso, Norway|Local Institution, Miraflores, Lima, Peru|Local Institution, Callao, Peru|Local Institution, Callao, Peru|Local Institution, Cusco, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Poznan, Wielkopolskie, Poland|Local Institution, Bialystok, Poland|Local Institution, Bydgoszcz, Poland|Local Institution, Bytom, Poland|Local Institution, Chojnice, Poland|Local Institution, Gdynia, Poland|Local Institution, Gdynia, Poland|Local Institution, Katowice, Poland|Local Institution, Kielce, Poland|Local Institution, Krakow, Poland|Local Institution, Krakow, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Lodz, Poland|Local Institution, Lodz, Poland|Local Institution, Lubin, Poland|Local Institution, Opole, Poland|Local Institution, Plock, Poland|Local Institution, Siemianowice Slaskie, Poland|Local Institution, Torun, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Wloclawek, Poland|Local Institution, Wroclaw, Poland|Local Institution, Wroclaw, Poland|Local Institution, Almada, Portugal|Local Institution, Aveiro, Portugal|Local Institution, Braga, Portugal|Local Institution, Coimbra, Portugal|Local Institution, Covilha, Portugal|Local Institution, Guimar?es, Portugal|Local Institution, Leiria, Portugal|Local Institution, Lisbon, Portugal|Local Institution, Senhora De Hora, Matosinhos, Portugal|Local Institution, Vila Real, Portugal|Local Institution, Caguas, Puerto Rico|Local Institution, Baia Mare, Romania|Local Institution, Brasov, Romania|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Oradea, Romania|Local Institution, Pitesti, Romania|Local Institution, Sibiu, Romania|Local Institution, Targoviste, Romania|Local Institution, Targu Mures, Romania|Local Institution, Timisoara, Romania|Local Institution, Timisoara, Romania|Local Institution, Tirgu Mures, Romania|Local Institution, Ekaterinburg, Russian Federation|Local Institution, Gatchina, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Krasnodar, Russian Federation|Local Institution, Krasnodar, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Samara, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Sochi, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Tyumen, Russian Federation|Local Institution, Tyumen, Russian Federation|Local Institution, Belgarde, Serbia|Local Institution, Belgrade, Serbia|Local Institution, Belgrade, Serbia|Local Institution, Nis, Serbia|Local Institution, Sremska Kamenica, Serbia|Local Institution, Uzice, Serbia|Local Institution, Banska Bystrica, Slovakia|Local Institution, Bardejov, Slovakia|Local Institution, Bratislava, Slovakia|Local Institution, Bratislava, Slovakia|Local Institution, Brezno, Slovakia|Local Institution, Kosice, Slovakia|Local Institution, Kosice, Slovakia|Local Institution, Kosice, Slovakia|Local Institution, Nitra, Slovakia|Local Institution, Spisska Nova Ves, Slovakia|Local Institution, Trebisov, Slovakia|Local Institution, Trencin, Slovakia|Local Institution, Majadahonda, Madrid, Spain|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Cordoba, Spain|Local Institution, Huelva, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Marbella, Spain|Local Institution, Palma de Mallorca, Spain|Local Institution, San Sebastian, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Eskilstuna, Sweden|Local Institution, Goteborg, Sweden|Local Institution, Jonkoping, Sweden|Local Institution, Ostersund, Sweden|Local Institution, Skelleftea, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Bern, Switzerland|Local Institution, Geneva, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Cherkasy, Ukraine|Local Institution, Chernivtsi, Ukraine|Local Institution, Dnipropetrovsk, Ukraine|Local Institution, Ivano-Frankivsk, Ukraine|Local Institution, Kharkiv, Ukraine|Local Institution, Kharkiv, Ukraine|Local Institution, Kharkiv, Ukraine|Local Institution, Kyiv, Ukraine|Local Institution, Kyiv, Ukraine|Local Institution, Kyiv, Ukraine|Local Institution, Lutsk, Ukraine|Local Institution, Lutsk, Ukraine|Local Institution, Mykolaiv, Ukraine|Local Institution, Odesa, Ukraine|Local Institution, Uzhhorod, Ukraine|Local Institution, Vinnytsia, Ukraine|Local Institution, Vinnytsia, Ukraine|Local Institution, Zhaporizhzhya, Ukraine|Local Institution, Bournemouth, Dorset, United Kingdom|Local Institution, Kirkcaldy, Fife, United Kingdom|Local Institution, Stevenage, Hertfordshire, United Kingdom|Local Institution, Liverpool, Merseyside, United Kingdom|Local Institution, Northampton, Northamptonshire, United Kingdom|Local Institution, Doncaster, South Yorkshire, United Kingdom|Local Institution, Sheffield, South Yorkshire, United Kingdom|Local Institution, Birmingham, United Kingdom|Local Institution, Dudley, West Midlands, United Kingdom|Local Institution, Dundee, United Kingdom|Local Institution, Wolverhampton, United Kingdom|Local Institution, Christiansted, Virgin Islands (U.S.)",https://ClinicalTrials.gov/show/NCT02415400
Completed,"Opioid Use Disorder, Severe|Opioid Use Disorder, Moderate",Drug: Sublocade,Indivior Inc.,17,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,21-Oct-19,25-Jan-21,"Hassman Research Institute, Berlin, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04060654
Completed,Opioid-use Disorder,Drug: TM buprenorphine|Drug: SUBLOCADE,Indivior Inc.,26,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,29-Aug-19,9-Dec-20,"Hassman Research Institute, Berlin, New Jersey, United States",https://ClinicalTrials.gov/show/NCT03993392
Completed,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: Netarsudil Ophthalmic Solution 0.02%,Aerie Pharmaceuticals,261,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,27-Dec-18,29-Sep-20,"Atlantis Eyecare, Huntington Beach, California, United States|Harvard Eye Associates, Laguna Hills, California, United States|North Bay Eye Associates, Inc, Petaluma, California, United States|Shettle Eye Research Inc, Largo, Florida, United States|Center For Sight, Sarasota, Florida, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Wheaton Eye Clinic, Ltd, Wheaton, Illinois, United States|Stiles Eyecare Excellence and Glaucoma Institute, PA, Overland Park, Kansas, United States|Gaddie Eye Centers, LLC, Louisville, Kentucky, United States|Glaucoma Consultants, Baltimore, Maryland, United States|Tekwani Vision Center, Saint Louis, Missouri, United States|Mark J. Weiss, M.D., Inc., Tulsa, Oklahoma, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Valley Eye Professionals, LLC, Huntingdon Valley, Pennsylvania, United States|Carolina Cataract & Laser Center, Ladson, South Carolina, United States|Total Eye Care, PA, Memphis, Tennessee, United States|VRF Eye Specialty Group, Memphis, Tennessee, United States|Advancing Vision Research, Nashville, Tennessee, United States|Keystone Research, Austin, Texas, United States|Cataract & Glaucoma Center, El Paso, Texas, United States|Houston Eye Associates, Houston, Texas, United States|The Eye Centers of Racine and Kenosha, Racine, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT03808688
Completed,Multiple Sclerosis,Other: Blood draw for future biomarker analysis,"Genzyme, a Sanofi Company|Sanofi",13,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,8-Feb-19,20-Jul-20,"Investigational Site Number 8400001, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT03784898
Completed,"Diabetes Mellitus, Type 2",Drug: Dulaglutide Pen|Drug: Semaglutide Pen,Eli Lilly and Company,312,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,18-Oct-18,24-Apr-20,"Valley Research, Fresno, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Palm Harbor Medical Associates, Palm Harbor, Florida, United States|Georgia Clinical Research, Snellville, Georgia, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|L-Marc Research Center, Louisville, Kentucky, United States|Evidera, Bethesda, Maryland, United States|Carolina Research Center, Inc., Shelby, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|BRCR Medical Center, Inc., Camp Hill, Pennsylvania, United States|Juno Research, Houston, Texas, United States|Juno Research, LLC, Houston, Texas, United States|PI-Coor Clinical Research, LLC, Annandale, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States",https://ClinicalTrials.gov/show/NCT03724981
Completed,"Diabetes Mellitus, Type 2",Drug: Insulin degludec|Drug: Insulin glargine,Novo Nordisk A/S,498,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2-Oct-18,12-Jan-21,"Novo Nordisk Investigational Site, Chandler, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, Van Nuys, California, United States|Novo Nordisk Investigational Site, Hamden, Connecticut, United States|Novo Nordisk Investigational Site, Bradenton, Florida, United States|Novo Nordisk Investigational Site, Cooper City, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Skokie, Illinois, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Kalispell, Montana, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Statesville, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, United States|Novo Nordisk Investigational Site, Dakota Dunes, South Dakota, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Kerrville, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Victoria, British Columbia, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Oakville, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Warsaw, Poland|Novo Nordisk Investigational Site, Ponce, Puerto Rico|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bytca, Slovakia|Novo Nordisk Investigational Site, Levice, Slovakia|Novo Nordisk Investigational Site, Malacky, Slovakia|Novo Nordisk Investigational Site, Nove Mesto nad Vahom, Slovakia|Novo Nordisk Investigational Site, Nove Zamky, Slovakia|Novo Nordisk Investigational Site, Trebisov, Slovakia|Novo Nordisk Investigational Site, Trnava, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Bloemfontein, Free State, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Lenasia, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa",https://ClinicalTrials.gov/show/NCT03687827
Completed,Glabellar Frown Lines,Biological: AbobotulinumtoxinA,Q-Med AB,120,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2-Oct-18,18-Mar-20,"Galderma Study Site, Los Angeles, California, United States|Galderma Study Site, San Francisco, California, United States|Galderma Study Site, Santa Monica, California, United States|Galderma Study Site, Greenwood Village, Colorado, United States|Galderma Study Site, Chicago, Illinois, United States|Galderma Study Site, Omaha, Nebraska, United States",https://ClinicalTrials.gov/show/NCT03687736
Completed,Cervical Intraepithelial Neoplasia,"Biological: HPV (Types 16, 18) Vaccine, Adsorbed",GlaxoSmithKline,3537,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,22-Aug-18,19-Dec-20,"GSK Investigational Site, Jintan, Jiangsu, China|GSK Investigational Site, Lianshui, Jiangsu, China|GSK Investigational Site, Xuzhou, Jiangsu, China|GSK Investigational Site, Yancheng, Jiangsu, China",https://ClinicalTrials.gov/show/NCT03629886
Completed,Schizophrenia|Schizoaffective Disorder|First Episode Psychosis,Device: Digital Medicine System|Drug: Aripiprazole|Drug: Olanzapine|Drug: Quetiapine|Drug: Risperidone,"Otsuka Pharmaceutical Development & Commercialization, Inc.",44,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,21-May-18,16-Jul-20,"Clinical Trial Site, Chertsey, United Kingdom|Clinical Trial Site, London, United Kingdom|Clinical Trial Site, Newcastle Upon Tyne, United Kingdom|Clinical Trial Site, Oxford, United Kingdom|Clinical Trial Site, Southampton, United Kingdom",https://ClinicalTrials.gov/show/NCT03568500
Completed,Actinic Keratoses,Drug: Methyl Aminolaevulinate 16% Cream,Galderma,50,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,7-Jun-17,10-Dec-20,"University Hospital Regensburg, Regensburg, Germany",https://ClinicalTrials.gov/show/NCT03511326
Completed,Idiopathic Pulmonary Fibrosis,Device: Littmann ®,Boehringer Ingelheim,274,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28-Mar-18,27-Jan-20,"Klinikum Chemnitz gGmbH, Chemnitz, Germany|Fachkrankenhaus Coswig GmbH, Coswig, Germany|Klinik Donaustauf, Donaustauf, Germany|Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen, Germany|Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany|Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg, Heidelberg, Germany|Klinikum Konstanz, Konstanz, Germany|Krankenhaus Bethanien gGmbH, Solingen, Germany",https://ClinicalTrials.gov/show/NCT03503188
Completed,Vaccination,Biological: IMVAMUNE®,Bavarian Nordic,22,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,22-Apr-10,19-Aug-20,"Palo Alto Medical Foundation, Palo Alto, California, United States",https://ClinicalTrials.gov/show/NCT03472014
Completed,"Pulmonary Disease, Chronic Obstructive",Drug: FF/UMEC/VI|Drug: Inhaled Corticosteroid|Drug: LAMA|Drug: LABA|Drug: COPD rescue medications,GlaxoSmithKline,3109,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-Apr-18,7-Sep-20,"GSK Investigational Site, Aschaffenburg, Bayern, Germany|GSK Investigational Site, Dachau, Bayern, Germany|GSK Investigational Site, Garmisch-Partenirchen, Bayern, Germany|GSK Investigational Site, Wallerfing, Bayern, Germany|GSK Investigational Site, Cottbus, Brandenburg, Germany|GSK Investigational Site, Fuerstenwalde, Brandenburg, Germany|GSK Investigational Site, Potsdam, Brandenburg, Germany|GSK Investigational Site, Potsdam, Brandenburg, Germany|GSK Investigational Site, Ruedersdorf, Brandenburg, Germany|GSK Investigational Site, Darmstadt, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Fulda, Hessen, Germany|GSK Investigational Site, Marburg, Hessen, Germany|GSK Investigational Site, Rodgau, Hessen, Germany|GSK Investigational Site, Ruesselsheim, Hessen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Peine, Niedersachsen, Germany|GSK Investigational Site, Wardenburg, Niedersachsen, Germany|GSK Investigational Site, Bergisch Gladbach, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Gelsenkirchen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Rheine, Nordrhein-Westfalen, Germany|GSK Investigational Site, Warendorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, Germany|GSK Investigational Site, Teuchern, Sachsen-Anhalt, Germany|GSK Investigational Site, Delitzsch, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Geesthacht, Schleswig-Holstein, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany|GSK Investigational Site, Schleswig, Schleswig-Holstein, Germany|GSK Investigational Site, Schmoelln, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Deggendorf, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Breda, Netherlands|GSK Investigational Site, Dordrecht, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Harderwijk, Netherlands|GSK Investigational Site, Heerlen, Netherlands|GSK Investigational Site, Hengelo, Netherlands|GSK Investigational Site, Hoorn, Netherlands|GSK Investigational Site, Kloosterhaar, Netherlands|GSK Investigational Site, Nijmegen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Zeist, Netherlands|GSK Investigational Site, Zutphen, Netherlands|GSK Investigational Site, Marbella - Málaga, Andalucia, Spain|GSK Investigational Site, Laredo, Cantabria, Spain|GSK Investigational Site, Torrejón de Ardoz, Madrid, Spain|GSK Investigational Site, Alcorcón (Madrid), Spain|GSK Investigational Site, Alzira/Valencia, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Basurto/Bilbao, Spain|GSK Investigational Site, Benalmádena, Málaga, Spain|GSK Investigational Site, Caceres, Spain|GSK Investigational Site, Cádiz, Spain|GSK Investigational Site, L'Hospitalet De Llobregat. Barcelona, Spain|GSK Investigational Site, La Roca Del Valles (Barcelona), Spain|GSK Investigational Site, Logroño, Spain|GSK Investigational Site, Loja/ Granada, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Ponferrada (León), Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, Segovia, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Vigo-Pontevedra, Spain|GSK Investigational Site, Zaragoza, Spain|GSK Investigational Site, Angered, Sweden|GSK Investigational Site, Flen, Sweden|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Härnösand, Sweden|GSK Investigational Site, Höllviken, Sweden|GSK Investigational Site, Kristianstad, Sweden|GSK Investigational Site, Kungsbacka, Sweden|GSK Investigational Site, Luleå, Sweden|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Motala, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Södertälje, Sweden|GSK Investigational Site, Trollhättan, Sweden|GSK Investigational Site, Örebro, Sweden|GSK Investigational Site, Östersund, Sweden|GSK Investigational Site, Soham, Cambridgeshire, United Kingdom|GSK Investigational Site, Llanelli, Carmarthenshire, United Kingdom|GSK Investigational Site, Bollington, Cheshire, United Kingdom|GSK Investigational Site, Macclesfield, Cheshire, United Kingdom|GSK Investigational Site, Sandbach, Cheshire, United Kingdom|GSK Investigational Site, Rhyl, Denbighshire, United Kingdom|GSK Investigational Site, Waterlooville, Hampshire, United Kingdom|GSK Investigational Site, Wishaw, Lanarkshire, United Kingdom|GSK Investigational Site, Corby, Northamptonshire, United Kingdom|GSK Investigational Site, Wellingborough, Northamptonshire, United Kingdom|GSK Investigational Site, Leiston, Suffolk, United Kingdom|GSK Investigational Site, Bexhill, Sussex East, United Kingdom|GSK Investigational Site, Gateshead, Tyne & Wear, United Kingdom|GSK Investigational Site, Bebington, United Kingdom|GSK Investigational Site, Buckley, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom|GSK Investigational Site, Colchester, United Kingdom|GSK Investigational Site, Corbridge, United Kingdom|GSK Investigational Site, Cornwall, United Kingdom|GSK Investigational Site, Edinburgh, United Kingdom|GSK Investigational Site, Hull, United Kingdom|GSK Investigational Site, Irlam, Manchester, United Kingdom|GSK Investigational Site, Larbet, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Newport, Isle Of Wight, United Kingdom|GSK Investigational Site, Newport, United Kingdom|GSK Investigational Site, Poole, United Kingdom|GSK Investigational Site, Southampton, United Kingdom|GSK Investigational Site, Swinton, United Kingdom|GSK Investigational Site, Warrington, United Kingdom",https://ClinicalTrials.gov/show/NCT03467425
Completed,Heart Failure (HF),Drug: Ivabradine,Amgen,30,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28-Sep-17,7-Apr-20,"Research Site, Wilmington, Delaware, United States|Research Site, Detroit, Michigan, United States|Research Site, Buffalo, New York, United States",https://ClinicalTrials.gov/show/NCT03456856
Completed,Non-Small Cell Lung Cancer (NSCLC)|Non-Small-Cell Lung Carcinoma|Nonsmall Cell Lung Cancer|Kidney Cancer|Kidney Neoplasms|Renal Cancer|Renal Neoplasms,Drug: Nivolumab,Bristol-Myers Squibb,100,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6-Mar-18,4-Dec-20,"Local Institution, Bangalore, India|Local Institution, Bangalore, India|Local Institution, Bengaluru, India|Local Institution, Hyderabad, India|Local Institution, Jaipur, India|Local Institution, Kolkata, India|Local Institution, Mumbai, India|Local Institution, New Delhi, India|Local Institution, Vellore, India",https://ClinicalTrials.gov/show/NCT03444766
Completed,Contour,Drug: BELKYRA®|Device: Juvéderm® VOLUMA™ with Lidocaine,Allergan,58,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2-Feb-18,31-Dec-20,"Darlinghurst Dermatology, Darlinghurst, New South Wales, Australia|Living Art, East Melbourne, Victoria, Australia|Dermatology Institute of Victoria, South Yarra, Victoria, Australia",https://ClinicalTrials.gov/show/NCT03425253
Completed,Asthma,Drug: RELVAR/BREO|Drug: Salbutamol|Device: Smart phone app|Device: HCP Dashboard|Device: Sensors,GlaxoSmithKline,437,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31-Jan-18,5-Feb-20,"GSK Investigational Site, Aventura, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Flossmoor, Illinois, United States|GSK Investigational Site, Glenview, Illinois, United States|GSK Investigational Site, Hazelwood, Missouri, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Ajax, Ontario, Canada|GSK Investigational Site, Burlington, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Sarnia, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Windsor, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Victoriaville, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Ruedersdorf, Brandenburg, Germany|GSK Investigational Site, Darmstadt, Hessen, Germany|GSK Investigational Site, Warendorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Salerno, Campania, Italy|GSK Investigational Site, Pordenone, Friuli-Venezia-Giulia, Italy|GSK Investigational Site, Palermo, Sicilia, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Breda, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Hengelo, Netherlands|GSK Investigational Site, Hoorn, Netherlands|GSK Investigational Site, Zutphen, Netherlands|GSK Investigational Site, Balenyà (Barcelona), Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, La Coruña, Spain|GSK Investigational Site, La Roca Del Valles (Barcelona), Spain|GSK Investigational Site, Loja/ Granada, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Peralada( Girona), Spain|GSK Investigational Site, Aylesbury, Buckinghamshire, United Kingdom|GSK Investigational Site, Wigan, Lancashire, United Kingdom|GSK Investigational Site, Wellingborough, Northamptonshire, United Kingdom|GSK Investigational Site, Addlestone, Surrey, United Kingdom|GSK Investigational Site, Rotherham, Yorkshire, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Chelmsford, United Kingdom|GSK Investigational Site, Chertsey, Surrey, United Kingdom|GSK Investigational Site, Harrogate, United Kingdom",https://ClinicalTrials.gov/show/NCT03380429
Completed,Back Pain|Leg Pain,Device: Spinal Cord Stimulation,MedtronicNeuro,30,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Nov-17,18-Mar-20,"Arizona Pain Doctors, Chandler, Arizona, United States|Georgia Pain and Wellness Center, Lawrenceville, Georgia, United States|Global Scientific Innovations, Evansville, Indiana, United States|Goodman Campbell Brain and Spine, Indianapolis, Indiana, United States|Kentuckiana Pain Specialists, Louisville, Kentucky, United States|Drez One, LLC, Somerset, Kentucky, United States|Regional Brain & Spine, Cape Girardeau, Missouri, United States|Precision Spine Care, Tyler, Texas, United States|Northwest Pain Care, Inc., Spokane, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT03284411
Terminated,Type 1 Diabetes Mellitus,"Drug: Insulin glargine, 300 units per milliliter (U/mL)|Drug: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)",Sanofi,15,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-Sep-17,7-Jan-20,"Investigational Site Number 8400002, West Des Moines, Iowa, United States|Investigational Site Number 8400004, Houston, Texas, United States|Investigational Site Number 8400003, Bridgeport, West Virginia, United States|Investigational Site Number 1240001, Barrie, Canada|Investigational Site Number 1240003, Oakville, Canada|Investigational Site Number 1240002, Thornhill, Canada",https://ClinicalTrials.gov/show/NCT03260868
Completed,"Hepatitis B, Chronic",Drug: Tenofovir Disoproxil Fumarate,GlaxoSmithKline,75,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2-Oct-17,2-Jan-20,"GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Ehime, Japan|GSK Investigational Site, Ehime, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hiroshima, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Nagasaki, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tottori, Japan",https://ClinicalTrials.gov/show/NCT03258710
Completed,Relapsing Multiple Sclerosis,Drug: Fingolimod,Novartis Pharmaceuticals|Novartis,382,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,19-Sep-17,21-Jul-20,"Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Cullman, Alabama, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Louisville, Colorado, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Port Charlotte, Florida, United States|Novartis Investigative Site, Sarasota, Florida, United States|Novartis Investigative Site, Sunrise, Florida, United States|Novartis Investigative Site, Vero Beach, Florida, United States|Novartis Investigative Site, Savannah, Georgia, United States|Novartis Investigative Site, Suwanee, Georgia, United States|Novartis Investigative Site, Flossmoor, Illinois, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Lutherville, Maryland, United States|Novartis Investigative Site, Foxboro, Massachusetts, United States|Novartis Investigative Site, Lexington, Massachusetts, United States|Novartis Investigative Site, Wellesley, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Owosso, Michigan, United States|Novartis Investigative Site, Golden Valley, Minnesota, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Fair Lawn, New Jersey, United States|Novartis Investigative Site, Livingston, New Jersey, United States|Novartis Investigative Site, Patchogue, New York, United States|Novartis Investigative Site, Plainview, New York, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Mooresville, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Westerville, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Greer, South Carolina, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, United States|Novartis Investigative Site, Port Royal, South Carolina, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Falls Church, Virginia, United States|Novartis Investigative Site, Vienna, Virginia, United States|Novartis Investigative Site, Kirkland, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Huntington, West Virginia, United States|Novartis Investigative Site, Green Bay, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Neenah, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT03257358
Completed,Bacterial Infections|Acute Bacterial Skin and Skin Structure Infection,Drug: Dalbavancin|Drug: Usual Care,Allergan,91,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,24-Jul-17,18-Jan-20,"Weill Cornell Medicine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03233438
Completed,"Pulmonary Disease, Chronic Obstructive",Device: ELLIPTA placebo DPI|Device: DISKUS placebo DPI|Device: HandiHaler placebo DPI|Other: Inhaler preference questionnaires,GlaxoSmithKline,240,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-Sep-17,9-Jan-20,"GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Natchitoches, Louisiana, United States|GSK Investigational Site, Saint Charles, Missouri, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Gastonia, North Carolina, United States|GSK Investigational Site, Monroe, North Carolina, United States|GSK Investigational Site, Mooresville, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Anderson, South Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Rock Hill, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT03227445
Completed,Epilepsy With Partial On-set Seizures,Drug: Eslicarbazepine acetate|Drug: Eslicarbazepine Acetate,Sunovion,102,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7-Jul-17,16-Jun-20,"University of South Alabaa Neurology Department, Mobile, Alabama, United States|Banner University Medical Center Phoenix=Neuroscience Institute, Phoenix, Arizona, United States|Rancho Research Institute, Inc., Downey, California, United States|Neuro-Pain Medical Center, Fresno, California, United States|Altman Clinical and Translational Research Institute, La Jolla, California, United States|University of California-Irvine, Orange, California, United States|Blue Sky Neurology, a Division of Carepoint PC, Englewood, Colorado, United States|University of Connecticut School of Mwdicine -UCONN Health, Farmington, Connecticut, United States|George Washington Medical Faculty Associates, Washington, District of Columbia, United States|Boca Raton Regional Hospital, Marcus Neuroscience Institute, Boca Raton, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|Neurology Associates PA, Maitland, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|Laszlo J. Mate, MD, PA, North Palm Beach, Florida, United States|Neurological Services of Orlando, PA, Orlando, Florida, United States|Pedicatric Neurology, PA, Orlando, Florida, United States|Medsol Clinical Research Center, Port Charlotte, Florida, United States|Tallahassee Neurological Clinic, Tallahassee, Florida, United States|University of South Florida, Tampa, Florida, United States|Vero Beach Neurology And Reasearch Institue/The MS Center of Vero Beach, Vero Beach, Florida, United States|Georgia Neurology and Sleep Medicine Associates, Suwanee, Georgia, United States|Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States|Conslutants in Epilepsy & Neurology, PLLC, Boise, Idaho, United States|Northwestern Medical Group, Deparment of Neurology, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Kentucky Hospital, Chandler Medical Center, Lexington, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States|Balijeet Shethi, MD, Waldorf, Maryland, United States|Wayne State University/Detroit Medical Center, Detroit, Michigan, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|Minnesota Epilepsy Group, PA, Saint Paul, Minnesota, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|JFK Neuroscience Institute, JFK Medical Center, Edison, New Jersey, United States|Clinical Research Center of NJ (CRCNJ), Voorhees, New Jersey, United States|NYU Winthrop Hospital, Clinical Trials Center, Mineola, New York, United States|UNC Inverstigal Drug Services, Chapel Hill, North Carolina, United States|The Neurological Institute, PA, Charlotte, North Carolina, United States|Wake Forest Baptist Health Sciences, Department of Neurology, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Providence Medical Group-Medford Neurology, Medford, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, United States|Alleghany General Hospital (Allegheny Neurological Association), Pittsburgh, Pennsylvania, United States|Vanderbilt Epilepsy Clinic, Nashville, Tennessee, United States|Austin Epilepsy Care Center, Austin, Texas, United States|Aston Ambulatory Care Center, Dallas, Texas, United States|University of Texas Health Science Center at San Antonio Medical Arts and Research Center, San Antonio, Texas, United States|SSM Health Dean Medical Group, Madison, Wisconsin, United States|Londo Health Sciences Centre, University Hospital, London, Ontario, Canada|Clinique D'Épilepsie Neuro Rive-Sud, Greenfield Park, Quebec, Canada",https://ClinicalTrials.gov/show/NCT03116828
Completed,Prostate Cancer,Drug: Leuprolide,Astellas Pharma Singapore Pte. Ltd.|Astellas Pharma Inc,107,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,23-Jun-17,9-Dec-20,"Site HK01001, Hong Kong, Hong Kong|Site HK01002, Hong Kong, Hong Kong|Site ID02001, Jakarta, DKI Jakarta, Indonesia|Site MY03002, Batu Caves, Selangor, Malaysia|Site MY03001, Kuala Lumpur, Malaysia|Site PH04001, Makati City, Metro Manila, Philippines|Site PH04003, Manila, Metro Manila, Philippines|Site PH04002, San Juan, Metro Manila, Philippines|Site SG05001, Singapore, Singapore|Site SG05002, Singapore, Singapore|Site SG05003, Singapore, Singapore|Site TW06001, Taichung, Taiwan|Site TW06002, Taichung, Taiwan|Site TW06003, Taipei, Taiwan|Site TH07001, Muang, Chiang Mai, Thailand|Site TH07004, Hat Yai, Songkhla, Thailand|Site TH07003, Bangkok, Thailand|Site VN08001, Ho Chi Minh City, Vietnam|Site VN08002, Ho Chi Minh City, Vietnam",https://ClinicalTrials.gov/show/NCT03035032
Completed,Axial Spondyloarthritis (axSpA)|Anterior Uveitis (AU),Drug: Certolizumab Pegol,UCB Biopharma SRL|UCB Pharma,89,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,21-Dec-16,31-Dec-20,"As0007 101, Brno, Czechia|As0007 103, Brno, Czechia|As0007 107, Brno, Czechia|As0007 108, Ostrava, Czechia|As0007 109, Pardubice, Czechia|As0007 102, Praha 2, Czechia|As0007 105, Praha, Czechia|As0007 301, Freiburg, Germany|As0007 302, München, Germany|As0007 303, Münster, Germany|As0007 401, Amsterdam, Netherlands|As0007 506, Białystok, Poland|As0007 510, Lublin, Poland|As0007 509, Poznań, Poland|As0007 511, Poznań, Poland|As0007 502, Toruń, Poland|As0007 501, Warszawa, Poland|As0007 505, Warszawa, Poland|As0007 504, Wrocław, Poland|As0007 507, Wrocław, Poland|As0007 508, Wrocław, Poland|As0007 604, Barcelona, Spain|As0007 601, Córdoba, Spain",https://ClinicalTrials.gov/show/NCT03020992
Completed,Type 2 Diabetes Mellitus,Drug: Insulin Analog Mid Mixture|Drug: Basal Insulin Analog,Eli Lilly and Company,814,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6-Feb-17,18-Mar-20,"Beijing Huaxin Hospital, Beijing, Beijing, China|Peking University Peoples Hospital, Beijing, Beijing, China|China Meitan General Hospital, Chaoyang, Beijing, China|Beijing Yanhua hospital, Fangshan, Beijing, China|The 2nd Hospital of Lanzhou University, Lanzhou, Gansu, China|Shenzhen City People Hospital, Shenzhen, Guangdong, China|The 1st Hospital with Guangdong Pharmaceutical University, Yuexiu, Guangdong, China|The 1st Affiliated Hospital of Henan Science and technology, Luoyang, Henan, China|People's Hospital of Henan Province, Zhengzhou, Henan, China|Wuhan Union (Xiehe) Hospital, Wuhan, Hubei, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|Nanjing TCM hospital, Nanjing, Jiangsu, China|Jiang Su Province Official Hospital, Nanjing, Jiangsu, China|Nanjing Jiangbei Hospital, Nanjing, Jiangsu, China|Nanjing Jiangning Hospital, Nanjing, Jiangsu, China|Taizhou City People Hospital, Taizhou, Jiangsu, China|The second People's hospital of Wuxi, Wuxi, Jiangsu, China|Xuzhou central Hospital, Xuzhou, Jiangsu, China|Qingdao Municipal Hospital, Qingdao, Shandong, China|Taian City Central Hospital, Taian, Shandong, China|Shanghai Pudong New Area Gongli Hospital, Shanghai, Shanghai, China|Shanghai Pudong New District Zhoupu Hospital, Shanghai, Shanghai, China|Affiliated Hospital of North Sichuan Medical College, Nanchong, Shunqing, China|The Third Affiliated Hospital of Chengdu University of TCM, Chengdu, Sichuan, China|Southwest Medical University Affiliated Hospital, Luzhou, Sichuan, China|Tianjin First Central Hospital, Nankai, Tianjin, China|Beijing LuHe Hospital Capital Medical University, Beijing, Tongzhou, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Ningbo First Hospital, Ningbo, Zhejiang, China|Peking University International Hospital, Beijing, China|Beijing Hai Dian Hospital, Beijing, China|Shanghai Yangpu District Central Hospital, Shanghai, China",https://ClinicalTrials.gov/show/NCT03018938
Completed,Acute Bacterial Skin and Skin Structure Infections,Drug: Usual Care|Drug: Dalbavancin,Allergan,313,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,29-Nov-16,10-Apr-20,"Maricopa Medical Center, Phoenix, Arizona, United States|Olive View-UCLA Medical Center, Sylmar, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Tampa General Hospital, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wayne State University, Detroit, Michigan, United States|ProMedica Monroe Regional Hospital, Monroe, Michigan, United States|Truman Medical Centers, Kansas City, Missouri, United States",https://ClinicalTrials.gov/show/NCT02961764
Completed,Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO),Biological: Ranibizumab|Radiation: Grid&Direct short pulse laser photocoagulation,Novartis Pharmaceuticals|Novartis,59,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-Dec-16,25-Feb-20,"Novartis Investigative Site, Nagakute-city, Aichi, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Kita-gun, Kagawa, Japan|Novartis Investigative Site, Tsu-city, Mie, Japan|Novartis Investigative Site, Matsumoto-city, Nagano, Japan|Novartis Investigative Site, Mitaka-city, Tokyo, Japan|Novartis Investigative Site, Hokkaido, Japan",https://ClinicalTrials.gov/show/NCT02953938
Completed,Pulmonary Arterial Hypertension,"Drug: Riociguat (Adempas, BAY63-2521)|Drug: Sildenafil|Drug: Tadalafil",Bayer,225,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-Jan-17,22-Jan-21,"Phoenix, Arizona, United States|Tucson, Arizona, United States|Sacramento, California, United States|Orlando, Florida, United States|Weston, Florida, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Detroit, Michigan, United States|Troy, Michigan, United States|Newark, New Jersey, United States|Mineola, New York, United States|New York, New York, United States|Rochester, New York, United States|Cleveland, Ohio, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Richmond, Virginia, United States|Graz, Austria|Leuven, Belgium|Belo Horizonte, Minas Gerais, Brazil|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Blumenal, Santa Catarina, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Montreal, Quebec, Canada|Praha 2, Czechia|Praha 4, Czechia|Aarhus N, Denmark|Le Kremlin-Bicêtre, France|Rouen, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Gießen, Germany|Hamburg, Germany|Chaidari, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Napoli, Campania, Italy|Roma, Lazio, Italy|Pavia, Lombardia, Italy|Palermo, Sicilia, Italy|Nagoya, Aichi, Japan|Sendai, Miyagi, Japan|Bunkyo-ku, Tokyo, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Culiacan, Sinaloa, Mexico|Mexico D.F., Mexico|Amsterdam, Netherlands|Nijmegen, Netherlands|Wroclaw, Poland|Almada, Lisboa, Portugal|Coimbra, Portugal|Lisboa, Portugal|Las Palmas de Gran Canaria, Las Palmas, Spain|Barcelona, Spain|Barcelona, Spain|Toledo, Spain|Kaoshiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Ankara, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Clydebank, West Dunbartonshire, United Kingdom|London, United Kingdom|London, United Kingdom|Sheffield, United Kingdom",https://ClinicalTrials.gov/show/NCT02891850
Completed,Asthma,Drug: ACT guided Routine Treatment|Drug: Routine Treatment,GlaxoSmithKline|MacroStat,530,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,26-Aug-16,3-Aug-20,"GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China",https://ClinicalTrials.gov/show/NCT02868281
Completed,Psoriatic Arthritis,Drug: methotrexate (MTX)|Biological: adalimumab (ADA),AbbVie,246,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5-Aug-16,23-Nov-20,"AZ Arthritis & Rheum Research /ID# 161796, Sun City, Arizona, United States|LeJenue Research Associates /ID# 200093, Miami, Florida, United States|Deerbrook Medical Associates /ID# 158655, Vernon Hills, Illinois, United States|Ochsner Clinic Foundation /ID# 155178, Baton Rouge, Louisiana, United States|Clinical Pharmacology Study Gr /ID# 161057, Worcester, Massachusetts, United States|Shores Rheumatology, PC /ID# 162697, Saint Clair Shores, Michigan, United States|Coastal Carolina Health Care /ID# 152088, New Bern, North Carolina, United States|PMG Research of Wilmington LLC /ID# 152089, Wilmington, North Carolina, United States|Altoona Ctr Clinical Res /ID# 152087, Duncansville, Pennsylvania, United States|Metroplex Clinical Research /ID# 162486, Dallas, Texas, United States|Swedish Medical Center /ID# 162051, Seattle, Washington, United States|West Virginia Research Inst /ID# 157815, South Charleston, West Virginia, United States|Royal Prince Alfred Hospital /ID# 153144, Camperdown, New South Wales, Australia|Optimus Clinical Research Pty. /ID# 153145, Kogarah, New South Wales, Australia|Liverpool Hospital /ID# 153147, Liverpool, New South Wales, Australia|BJC Health /ID# 153875, Paramatta, New South Wales, Australia|Box Hill Hospital /ID# 153146, Melbourne, Victoria, Australia|Hospital de Clinicas de Porto Alegre /ID# 152345, Porto Alegre, Rio Grande Do Sul, Brazil|Faculdade de Medicina do ABC /ID# 152344, Santo André, Sao Paulo, Brazil|MHAT Trimontsium /ID# 152658, Plovdiv, Bulgaria|Diag Consult Ctr 17 Sofia EOOD /ID# 152657, Sofia, Bulgaria|Rheumatology Research Assoc /ID# 161600, Edmonton, Alberta, Canada|Percuro Clinical Research, Ltd /ID# 161601, Victoria, British Columbia, Canada|Manitoba Clinic /ID# 151939, Winnipeg, Manitoba, Canada|St. Clare's Mercy Hospital /ID# 159680, St. John's, Newfoundland and Labrador, Canada|The Waterside Clinic /ID# 151938, Barrie, Ontario, Canada|Adachi Medicine Prof. Corp /ID# 152575, Hamilton, Ontario, Canada|Ctr. de Rheum de l'est du QC /ID# 151937, Rimouski, Quebec, Canada|Groupe de Recherche en Maladies Osseuses /ID# 205693, Sainte-foy, Quebec, Canada|Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 151954, Bogota, Cundinamarca, Colombia|Riesgo de Fractura S.A - CAYRE /ID# 153817, Bogota, Colombia|San Vicente Fundacion /Id# 171324, Medellin, Colombia|Revmatolog s.r.o. /ID# 151753, Jihlava 1, Jihlava, Czechia|Nuselská poliklinika, Revmatologie /ID# 151754, Prague 4, Praha 4, Czechia|Universitaetsklinik Heidelberg /ID# 152229, Heidelberg, Baden-Wuerttemberg, Germany|Fachpraxis fuer Rheumatologie und Osteologie /ID# 203982, Bruchhausen-Vilsen, Niedersachsen, Germany|Univ Hosp Schleswig-Holstein, Campus Kiel, Klinik furer Innere Medizin /ID# 152231, Kiel, Schleswig-Holstein, Germany|CIRI GmbH /ID# 152228, Frankfurt, Germany|Hamburger Rheuma I /ID# 164055, Hamburg, Germany|Universita di Catanzaro Magna Graecia /ID# 152013, Catanzaro, Calabria, Italy|Azienda Ospedaliera Policlinic /ID# 152011, Rome, Italy|A.O. Universitaria Senese /ID# 152012, Siena, Italy|McBk Sc /Id# 163089, Grodzisk Mazowiecki, Mazowieckie, Poland|Centrum Medyczne AMED /ID# 164047, Warsaw, Mazowieckie, Poland|SANUS Szpital Specjalistyczny /ID# 151988, Stalowa Wola, Podkarpackie, Poland|ClinicMed Badurski i wspolnicy SJ /ID# 151987, Bialystok, Poland|Dr. Ramon L. Ortega-Colon, MD /ID# 152957, Carolina, Puerto Rico|GCM Medical Group, PSC /ID# 152091, San Juan, Puerto Rico|Hamad Hospital /ID# 152334, Doha, Ad Dawhah, Qatar|Corporac Sanitaria Parc Tauli /ID# 151759, Sabadell, Barcelona, Spain|Hospital Univ Germans Trias I Pujol /ID# 151760, Badalona, Spain|Hospital Universitario Reina S /ID# 151761, Cordoba, Spain|Hospital Manises /ID# 162778, Manises, Spain|Hospital Univ Canarias /ID# 206489, Santa Cruz de Tenerife, Spain|Hospital de Viladecans /ID# 163875, Viladecans, Spain|Royal National Hosp for Rheuma /ID# 152767, Bath, United Kingdom|Western General Hospital /ID# 155195, Edinburgh, United Kingdom|Altnagelvin Area Hospital /ID# 152766, Londonderry, United Kingdom|Central Manchester University /ID# 152765, Manchester, United Kingdom|Lancashire Care NHS Foundation /ID# 152769, Preston, United Kingdom",https://ClinicalTrials.gov/show/NCT02814175
Completed,Central Retinal Vein Occlusion,"Drug: Aflibercept (Eylea, BAY86-5321)",Bayer,162,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-Jun-16,8-Jul-20,"Albury, New South Wales, Australia|Sydney, New South Wales, Australia|Parramatta, Australia|Calgary, Alberta, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Boisbriand, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Aalborg, Denmark|Glostrup, Denmark|Bordeaux, France|Dijon Cedex, France|Lyon, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Karlsruhe, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Göttingen, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Hannover, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Roma, Lazio, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Ancona, Marche, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Oviedo, Asturias, Spain|Sant Cugat del Vallés, Barcelona, Spain|Viladecans, Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Sunderland, Tyne And Wear, United Kingdom|Bradford, West Yorkshire, United Kingdom|Bristol, United Kingdom|Colchester, United Kingdom|Liverpool, United Kingdom|Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT02800642
Completed,Plaque Psoriasis,"Drug: DFD-01 (betamethasone dipropionate) Spray, 0.05%","Promius Pharma, LLC",45,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Feb-16,5-Oct-20,"Site Four, Arlington Heights, Illinois, United States|Site Two, New Albany, Indiana, United States|Site One, Louisville, Kentucky, United States|Site Three, Las Vegas, Nevada, United States",https://ClinicalTrials.gov/show/NCT02749799
Completed,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: alpha-glucosidase inhibitors|Drug: DPP-4 inhibitors|Drug: meglitinides|Drug: SGLT-2 inhibitors|Drug: sulphonylurea|Drug: thiazolidinediones,Novo Nordisk A/S,1991,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28-Mar-16,7-Jul-20,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Haleyville, Alabama, United States|Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Fountain Hills, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tempe, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Harrisburg, Arkansas, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, North Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, United States|Novo Nordisk Investigational Site, Alhambra, California, United States|Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Carlsbad, California, United States|Novo Nordisk Investigational Site, Coronado, California, United States|Novo Nordisk Investigational Site, Costa Mesa, California, United States|Novo Nordisk Investigational Site, Elk Grove, California, United States|Novo Nordisk Investigational Site, Encinitas, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Mirada, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Montclair, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Oxnard, California, United States|Novo Nordisk Investigational Site, Rancho Cucamonga, California, United States|Novo Nordisk Investigational Site, Riverside, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Westminster, California, United States|Novo Nordisk Investigational Site, Centennial, Colorado, United States|Novo Nordisk Investigational Site, Centennial, Colorado, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Monument, Colorado, United States|Novo Nordisk Investigational Site, Chiefland, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Kissimmee, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Ocala, Florida, United States|Novo Nordisk Investigational Site, Ocoee, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Ormond Beach, Florida, United States|Novo Nordisk Investigational Site, Oviedo, Florida, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Saint Petersburg, Florida, United States|Novo Nordisk Investigational Site, Seminole, Florida, United States|Novo Nordisk Investigational Site, Bainbridge, Georgia, United States|Novo Nordisk Investigational Site, Conyers, Georgia, United States|Novo Nordisk Investigational Site, Perry, Georgia, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, United States|Novo Nordisk Investigational Site, Woodstock, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Aurora, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, United States|Novo Nordisk Investigational Site, Wauconda, Illinois, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Evansville, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Newton, Kansas, United States|Novo Nordisk Investigational Site, Park City, Kansas, United States|Novo Nordisk Investigational Site, Wichita, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Natchitoches, Louisiana, United States|Novo Nordisk Investigational Site, Shreveport, Louisiana, United States|Novo Nordisk Investigational Site, Sunset, Louisiana, United States|Novo Nordisk Investigational Site, Elkridge, Maryland, United States|Novo Nordisk Investigational Site, Oxon Hill, Maryland, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Rochester, Michigan, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Belzoni, Mississippi, United States|Novo Nordisk Investigational Site, Port Gibson, Mississippi, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Missoula, Montana, United States|Novo Nordisk Investigational Site, Fremont, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, North Massapequa, New York, United States|Novo Nordisk Investigational Site, Westfield, New York, United States|Novo Nordisk Investigational Site, Asheboro, North Carolina, United States|Novo Nordisk Investigational Site, Burlington, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Elizabeth City, North Carolina, United States|Novo Nordisk Investigational Site, Garner, North Carolina, United States|Novo Nordisk Investigational Site, Mooresville, North Carolina, United States|Novo Nordisk Investigational Site, Morganton, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, United States|Novo Nordisk Investigational Site, Edmond, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Fleetwood, Pennsylvania, United States|Novo Nordisk Investigational Site, Harleysville, Pennsylvania, United States|Novo Nordisk Investigational Site, Jersey Shore, Pennsylvania, United States|Novo Nordisk Investigational Site, Lansdale, Pennsylvania, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Smithfield, Pennsylvania, United States|Novo Nordisk Investigational Site, Uniontown, Pennsylvania, United States|Novo Nordisk Investigational Site, Providence, Rhode Island, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, United States|Novo Nordisk Investigational Site, Columbia, South Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Indian Land, South Carolina, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, United States|Novo Nordisk Investigational Site, Simpsonville, South Carolina, United States|Novo Nordisk Investigational Site, Rapid City, South Dakota, United States|Novo Nordisk Investigational Site, Athens, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Tullahoma, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Carrollton, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Georgetown, Texas, United States|Novo Nordisk Investigational Site, Gonzales, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Irving, Texas, United States|Novo Nordisk Investigational Site, Kerrville, Texas, United States|Novo Nordisk Investigational Site, Killeen, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, Missouri City, Texas, United States|Novo Nordisk Investigational Site, New Braunfels, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Splendora, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, Bountiful, Utah, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Danville, Virginia, United States|Novo Nordisk Investigational Site, Gloucester Courthouse, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Bellevue, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Walla Walla, Washington, United States|Novo Nordisk Investigational Site, Surrey, British Columbia, Canada|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Truro, Nova Scotia, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Strathroy, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Waterloo, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, St-Marc-des-Carrières, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Bogota, Colombia|Novo Nordisk Investigational Site, Bogota, Colombia|Novo Nordisk Investigational Site, Medellin, Colombia|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Mysore, Karnataka, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Hyderabad, Telengana, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Noida, Uttar Pradesh, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Hubli, India|Novo Nordisk Investigational Site, Ludhiana, India|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Tukums, Latvia|Novo Nordisk Investigational Site, Achrafieh, Lebanon|Novo Nordisk Investigational Site, Beirut, Lebanon|Novo Nordisk Investigational Site, Hazmieh, Lebanon|Novo Nordisk Investigational Site, Jbeil, Lebanon|Novo Nordisk Investigational Site, Toa Baja, Puerto Rico|Novo Nordisk Investigational Site, Trujillo Alto, Puerto Rico|Novo Nordisk Investigational Site, Dzerzhinskiy, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Adapazari, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT02730377
Terminated,Pressure Ulcer,Biological: Santyl|Biological: SoloSite®,"Smith & Nephew, Inc.",3,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Aug-16,10-Mar-20,"Lee's Summit, Missouri, United States",https://ClinicalTrials.gov/show/NCT02718625
Completed,Breast Cancer,Drug: Palbociclib|Drug: Letrozole,Pfizer,252,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,9-Mar-16,5-Oct-20,"Benjamin Carl Forster, North Sydney, New South Wales, Australia|Dr. Alexander Maxwell Menzies, North Sydney, New South Wales, Australia|HPS Pharmacies - North Sydney, North Sydney, New South Wales, Australia|Mater Hospital Sydney, North Sydney, New South Wales, Australia|Professor Frances Mary Boyle, North Sydney, New South Wales, Australia|Royal North Shore Hospital - Clinical Trials Pharmacy, St Leonards, New South Wales, Australia|Royal North Shore Hospital, Dept. of Medical Oncology, St Leonards, New South Wales, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|River City Pharmacy, Auchenflower, Queensland, Australia|Icon Cancer Care Chermside, Chermside, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Icon Cancer Care, Corporate Office, South Brisbane, Queensland, Australia|Icon Cancer Care Southport, Southport, Queensland, Australia|Flinders Medical Centre-Pharmacy Department, Bedford Park, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Monash Health, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre Pharmacy, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Sunshine Hospital Pharmacy, St. Albans, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Pharmacy Department, Murdoch, Western Australia, Australia|Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India|Dr. B.R.A Institute Rotary Cancer Hospital, All India Institue of Medical Sciences, New Delhi, Delhi, India|The Gujarat Cancer & Research Institute, M.P Shah Cancer Hospital, Ahmedabad, Gujarat, India|Manipal Hospital, Bangalore, Karnataka, India|HealthCare Global Enterprises Ltd., Bangalore, Karnataka, India|Kasturba Hospital, Manipal, Karnataka, India|Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India|Meditrina Institute Of Medical Sciences, Nagpur, Maharashtra, India|Shatabdi Hospital, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Apollo Speciality Hospital, Chennai, Tamilnadu, India",https://ClinicalTrials.gov/show/NCT02679755
Completed,Coronary Artery Disease,Drug: 3 months of dual antiplatelet therapy (DAPT)|Device: SYNERGY Stent System,Boston Scientific Corporation,2009,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-Feb-16,25-Sep-20,"Banner Good Samaritan Regional Medical Center, Phoenix, Arizona, United States|St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States|Baptist Health Medical Center (Little Rock), Little Rock, Arkansas, United States|Arkansas Heart Hospital, Little Rock, Arkansas, United States|Bakersfield Memorial Hospital, Bakersfield, California, United States|USC Medical Center, Los Angeles, California, United States|Cedars - Sinai Medical Center, Los Angeles, California, United States|El Camino Hospital, Mountain View, California, United States|HCA Riverside Community Hospital, Riverside, California, United States|Sutter Medical Center, Sacramento, Sacramento, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|Kaiser Foundation Hospital - San Francisco, San Francisco, California, United States|John Muir Medical Center, Walnut Creek, California, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Washington Hospital Center, Washington, District of Columbia, United States|JFK Medical Center, Atlantis, Florida, United States|Morton Plant Mease Healthcare System, Clearwater, Florida, United States|North Florida Regional Medical Center, Gainesville, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mediquest Research at Munroe Regional Medical Center, Ocala, Florida, United States|Florida Hospital, Orlando, Florida, United States|Florida Hospital Heartland Medical Center, Sebring, Florida, United States|Tallahassee Memorial Hospital, Tallahassee, Florida, United States|University Hospital, Augusta, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|Wellstar Kennestone Hospital, Marietta, Georgia, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Edward Hospital, Naperville, Illinois, United States|St. John's Hospital, Springfield, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Franciscan St. Francis Hospital, Beech Grove, Indiana, United States|Northern Indiana Research Alliance - Lutheran Hospital, Fort Wayne, Indiana, United States|Community Heart and Vascular Hospital, Indianapolis, Indiana, United States|Mercy Hospital Medical Center, Des Moines, Iowa, United States|Jewish Hospital and St. Mary's Healthcare, Louisville, Kentucky, United States|Cardiovascular Research, LLC, Shreveport, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Union Memorial Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|St. Mary's Duluth Clinic Regional Heart Center, Duluth, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|HealthEast St. Joseph's Hospital, Saint Paul, Minnesota, United States|St. Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cox Medical Centers, Springfield, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Deborah Heart and Lung Center, Browns Mills, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Presbyterian Hospital, Albuquerque, New Mexico, United States|North Shore University Hospital, Manhasset, New York, United States|New York University Medical Center, New York, New York, United States|Columbia University Medical Center/ NewYork Presbyterian Hospital, New York, New York, United States|St. Joseph's Hospital Health Center, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Wake Medical Center, Raleigh, North Carolina, United States|Lindner Center for Research and Education at Christ Hospital, Cincinnati, Ohio, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|OhioHealth Research and Innovation Institute - Riverside Methodist Hospital, Columbus, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Lankenau Hospital, Wynnewood, Pennsylvania, United States|Sisters of Charity Providence Hospital, Columbia, South Carolina, United States|University Medical Center-Greenville Memorial Hospital, Greenville, South Carolina, United States|Grand Strand Regional Medical Center, Myrtle Beach, South Carolina, United States|Jackson-Madison County General Hospital, Jackson, Tennessee, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|Centennial Medical Center, Nashville, Tennessee, United States|Baylor Heart & Vascular Hospital, Dallas, Texas, United States|St. Luke's Episcopal Hospital, Houston, Texas, United States|The Heart Hospital Baylor Plano, Plano, Texas, United States|St. David's Round Rock Medical Center, Round Rock, Texas, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Winchester Medical Center, Winchester, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Charleston Area Medical Center, Charleston, West Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Aspirus Heart and Vascular Institute - Research and Education, Wausau, Wisconsin, United States|Instituto do Coração (InCor), Sao Paulo, Brazil|Instituto de Cardiologia Dante Pazzanese, São Paulo, Brazil|Herzzentrum Bad Krozingen, Bad Krozingen, Germany|Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH, Bad Segeberg, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Uni Jena, Jena, Germany|Fukuoka Sanno Hospital, Fukuoka-shi, Fukuoka, Japan|Iwate Medical University Hospital, Morioka-shi, Iwate-ken, Japan|Tokai University Hospital, Isehara-shi, Kanagawa, Japan|Shonan Kamakura General Hospital, Kamakura-shi, Kanagawa, Japan|Saiseikai Yokohama-City Eastern Hospital, Yokohama-shi, Kanagawa, Japan|Mitsui Memorial Hospital, Chiyoda-ku, Tokyo, Japan|Teikyo University Hospital, Itabashi-ku, Tokyo, Japan|Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan|Kurume University Hospital, Kurume-shi, Japan|Osaka Saiseikai Nakatsu Hospital, Osaka, Japan|P. Stradins University Hospital, Riga, Latvia|Falu Lasarett, Falun, Sweden|Karlstadt Central Hospital, Karlstad, Sweden|Skane University Hospital, Malmo, Sweden|Hospital Cantonal Fribourg, Fribourg, Switzerland",https://ClinicalTrials.gov/show/NCT02605447
Completed,Relapsing-Remitting Multiple Sclerosis (RRMS),Drug: peginterferon beta-1a,Biogen,193,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3-Feb-16,13-Jan-20,"Research Site, Arezzo, Italy|Research Site, Bari, Italy|Research Site, Cagliari, Italy|Research Site, Cefalù, Italy|Research Site, Chieti, Italy|Research Site, Como, Italy|Research Site, Fidenza, Italy|Research Site, Foligno, Italy|Research Site, Gallarate, Italy|Research Site, Genova, Italy|Research Site, L'Aquila, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Mondovì, Italy|research Site, Napoli, Italy|Research Site, Napoli, Italy|Research Site, Orbassano, Italy|Research Site, Ozieri, Italy|Research Site, Palermo, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Pietra Ligure, Italy|Research Site, Pozzilli, Italy|Research Site, Reggio Calabria, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy",https://ClinicalTrials.gov/show/NCT02587065
Completed,"Colitis, Ulcerative|Crohn's Disease",Drug: Vedolizumab,Takeda,11,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,29-Nov-17,4-Mar-20,"University of Colorado, Aurora, Colorado, United States|Feinberg School of Medicine Northwestern University, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Atlantic Health System, Morristown, New Jersey, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT02559713
Completed,Pain,Drug: Bupivacaine FNB|Drug: EXPAREL Infiltration,"Pacira Pharmaceuticals, Inc",23,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sep-14,24-Nov-20,"Research Concepts, GP, LLC, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT02255500
Completed,Deep Vein Thrombosis|Post-thrombotic Syndrome,Device: EkoSonic® Endovascular System|Biological: Alteplase,EKOS Corporation|BTG International Inc.,81,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-Jul-14,18-Feb-20,"UCLA Medical Center, Los Angeles, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Vascular Breakthroughs, Darien, Connecticut, United States|Christiana Hospital, Newark, Delaware, United States|Tampa General Hospital, Tampa, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|CHI Health St. Elizabeth, Lincoln, Nebraska, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|NYU Langone Medical Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Aultman Hospital, Canton, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|DFW Vascular Group/ Methodist Dallas Medical Ctr, Dallas, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States|Inova Alexandria Hospital, Alexandria, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States",https://ClinicalTrials.gov/show/NCT02159521
Completed,Myelodysplastic Syndromes,Drug: Epoetin beta,Hoffmann-La Roche,100,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6-Aug-14,24-Apr-20,"King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Rajavithi Hospital; Medicine, Bangkok, Thailand|Ramathibodi Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Siriraj Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Chiang Mai Uni Hospital; Division of Hematology,Dept of Medicine,Faculty of Medicine, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine, Khon Kaen, Thailand|Khonkean Regional Hospital; Medicine, Khon Kean, Thailand|Thammasart Chalermprakiert Hospital, Thammasart Uni; Hematology, Pathumthani, Thailand|Naresaun University hospital, Phitsanulok, Thailand|Sapprasitthiprasong Hospital, Ubon Ratchathani, Thailand",https://ClinicalTrials.gov/show/NCT02145026
Completed,Iron Deficiency Anemia Secondary to IBD or Gastric Bypass,Drug: Injectafer|Drug: Ferrous Sulfate tablets,"American Regent, Inc.",198,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Jan-14,17-Sep-20,,https://ClinicalTrials.gov/show/NCT02086968
Terminated,Paroxysmal Atrial Fibrillation,Other: Off OAT Group (Test)|Other: On OAT Group (Control),"Biosense Webster, Inc.",80,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,17-Apr-13,17-Dec-20,"University of Kansas Hospitals, Kansas City, Kansas, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Texas Cardiac Arrhythmia Research Foundation, Austin, Texas, United States|Le Centre Hospitalier de Bordeaux, Bordeaux, Pessac, France|Asklepios Klinik St. Georg, Hamburg, Germany|Ospedale dell'Angelo, Mestre, Venezia, Italy",https://ClinicalTrials.gov/show/NCT01959425
Completed,Actinic Keratosis (AK),"Drug: Ingenol Mebutate Gel, 0.015%|Drug: Imiquimod Cream, 5%",LEO Pharma,485,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-Sep-13,29-Jul-20,"CHU Angers - Service de Dermatologie, Angers, France|CHU Besançon - Hôpital Jean Minjoz, Besançon, France|HOPITAL AVICENNE - Service de Dermatologie, Bobigny, France|CHRU de Brest - Hôpital Morvan - Service de Dermatologie, Brest, France|CHU Albert Michallon - Service de Dermatologie, Pôle Pluridisciplinaire de Médecine, Grenoble, France|Hôpital Claude Huriez - CHRU de Lille - Clinique de Dermatologie, Lille, France|Hôpital de la Timone - Service de Dermatologie Vénérologie, Marseille, France|CHU de Nantes - Hôtel Dieu - Unité Fonctionnelle de Dermatologie Cancérologie, Nantes, France|HOPITAL DE L ARCHET II - Service de Dermatologie-Vénérologie, Nice, France|Hôpital Caremeau, Nimes, France|HOPITAL COCHIN TARNIER - Service de Dermatologie, Paris, France|Hôpital Saint Louis - Service de Dermatologie, Paris, France|CHU BORDEAUX - Hôpital Haut-Lévêque, Pessac, France|CHU Poitiers - Service de Dermatologie, Poitiers, France|C.H.U. de Saint-Etienne - Hôpital Nord, Saint-Etienne, France|Hôpital d'instruction des Armées Bégin - Clinique Dermatologique, St Mandé, France|Hautarztpraxis Simon, Berlin, Germany|Hauttumorzentrum Bochum Universitätsklinikum der Ruhr-Universität-Bochum, Bochum, Germany|Praxis Streit Bucholz, Buchholz, Germany|Dermatologisches Zentrum, Am Krankenhaus 1, Buxtehude, Germany|Klinikum Dortmund - Hautklinik, Dortmund, Germany|Mensingderma, Hamburg, Germany|Universitätsklinikum Leipzig Klinik für Dermatologie, Venerologie und Allergologie, Leipzig, Germany|Hautpraxis Dr. Ina Schulze, Markkleeberg, Germany|Hauttumorzentrum Münster, Münster, Germany|Klinik für Dermatologie und Allergologie, Klinikum Vest, Behandlungszentrum, Knappschaftskrankenhaus Recklinghausen,, Recklinghausen, Germany|Universitätklinikum Regensburg, Regensburg, Germany|Praxis Dr. Hoffmann, Witten, Germany|Praxis Derma Hübinger, Wuppertal, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Ninewells Hospital, Dundee, Angus, United Kingdom|Cumberland Infirmary, Carlisle, Cumbria, United Kingdom|Heavitree Hospital, Exeter, Devon, United Kingdom|Brighton General Hospital, Brighton, East Sussex, United Kingdom|Manchester Royal Infirmary, Manchester, Greater Manchester, United Kingdom|Monklands Hospital, Airdrie, Lanarkshire, United Kingdom|Scunthorpe General Hospital, Scunthorpe, Lincolnshire, United Kingdom|Royal Gwent Hospital, Newport, Monmouthshire, United Kingdom|Harrogate District Hospital, Harrogate, North Yorkshire, United Kingdom|Scarborough Hospital, Scarborough, North Yorkshire, United Kingdom|Cannock Chase Hospital, Cannock, Staffordshire, United Kingdom|East Surrey Hospital, Redhill, Surrey, United Kingdom|Southlands Hospital, Shoreham-by-Sea, West Sussex, United Kingdom|St Luke's Hospital, Bradford, West Yorkshire, United Kingdom|Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom",https://ClinicalTrials.gov/show/NCT01926496
Completed,Influenza,Drug: Ergoferon|Drug: Oseltamivir,Materia Medica Holding,184,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-Feb-15,3-Apr-20,"The Non-State Health Care Institution ""Road Hospital of the Open Joint Stock Company"" Russian Railways"", Chelyabinsk, Russian Federation|The State Budgetary Educational Institution of Higher Professional Education "" Kazan State University of Medicine"" Ministry of Health of the Russian Federation, Kazan, Russian Federation|Pirogov Russian National Research Medical University, Moscow, Russian Federation|Limited Liability Company ""Scientific Research Centre Eco-safety"", Saint Petersburg, Russian Federation|Regional State Budgetary Healthcare Institution ""Clinical Hospital №1"", Smolensk, Russian Federation|Federal State Budgetary Military Educational Institution of Higher Professional Education ""Military-Medicine Academy named after S. M. Kirov"" of Ministry of Defence of Russian Federation, St. Petersburg, Russian Federation|St. Petersburg State Budgetary Health Care Institution "" City policlinic No. 117"", St. Petersburg, Russian Federation",https://ClinicalTrials.gov/show/NCT01850446
Completed,Allergic Contact Dermatitis,Drug: Ethylenediamine dihydrochloride allergen patch,Allerderm,16,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Jul-12,28-May-20,"Dermatology Specialists PSC, Louisville, Kentucky, United States",https://ClinicalTrials.gov/show/NCT01798589
Completed,Prostate Cancer,Drug: Triptorelin 11.25 mg,Ipsen,226,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-Dec-12,9-Dec-20,"Chinese PLA General HospitalDepartment of UrologySite #156007, Beijing, China|Peiking University First Hospital Site #156011, Beijing, China|West China Hosspital, Sichuan UniversityDepartment of Urology Site #156008, Chengdu, China|The First Affiliated Hospital of the 3th Military Medical University of PLA (Southwest Hospital) Site # 156010, Chongqing, China|SUN YAT-SEN Cancer Center Department of Site #156009, Guangzhou, China|The third hospital affiliated to Sun Yat-sen University Site #156005, Guangzhou, China|The first hospital affiliated to medical school of Zhejiang university Site #156001, Hangzhou, China|Fudan University cancer hospital Site #156003, Shanghai, China|First Affiliated Hospital of the Fourth Military Medical University Site #156004, Xi'an, China|SIH Altaian Territorial Oncological Dispensary Site #643006, Barnaul, Russian Federation|SBHI Sverdlovskaya Regional Clinical Hospital #1 Site #643004, Ekaterinburg, Russian Federation|FSBI ""Research Institute of Urology"" of Ministry of health care of Russia Site #643002, Moscow, Russian Federation|State Budgetary Healthcare Institution ""Moscow Clinical Scientific-Practical Center named after A. S. Loginov of Healthcare Department of Moscow"" Site #643009, Moscow, Russian Federation|FSBI Russian Oncological Scientific Center named after N.N. Blokhina of RAMS, 23 Site #643001, Moscow, Russian Federation|Federal State Budgetary Health care Institution ""Central clinical hospital of Russian Academy of Science (CCH RAS), in-patient unit, urological department Site #643005, Moscow, Russian Federation|FSI Moscow Research Oncological Institute named after P.A.Gertsen Site #643003, Moscow, Russian Federation|Medical radiology research center named after A.F. Tsyba - branch of FSBI ""National Medical Research Center of Radiology"" of Ministry of healthcare of Russian Federation Site #643008, Obninsk, Russian Federation|Budgetary Health care Institution of Omsk region ""Clinical oncological dispensary"" Site #643007, Omsk, Russian Federation",https://ClinicalTrials.gov/show/NCT01753297
Completed,Neoplasms,Drug: Vemurafenib,Hoffmann-La Roche,215,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-Feb-13,18-Nov-20,"Highlands Oncology Group, Rogers, Arkansas, United States|UCLA Department of Medicine, Los Angeles, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|University of Chicago Medical Center; Medicine, Section of Pulmonary, Chicago, Illinois, United States|Siouxland Regional Cancer Center d/b/a June E. Nylen Cancer Center, Sioux City, Iowa, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|New York University Medical Center PRIME, New York, New York, United States|Evelyn H. Lauder Center, New York, New York, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Mary Crowley Medical Research Center; Oncology, Dallas, Texas, United States|M D Anderson Physician Network, Webster, Texas, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|N.N. Alexandrov National Cancer Centre of Belarus, Minsk District, Belarus|Institut Jules Bordet, Brussels, Belgium|University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|University Clinic Centre Sarajevo, Sarajevo, Bosnia and Herzegovina|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Bank of Cyprus Oncology Center, Nicosia, Cyprus|Medical Research Institute, Alexandria, Egypt|National Cancer Institute, Cairo, Egypt|Mansoura University Hospital, Dakahlia, Egypt|Gharbia Cancer Society, Tanta, Egypt|Centre Léon Bérard, Lyon, France|Institut Gustave Roussy, Villejuif, France|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz; Apotheke, Mainz, Germany|Universitätsklinikum Wurzburg, Würzburg, Germany|University General Hospital of Heraklion, Crete, Greece|Semmelweis Egyetem, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont; Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary|Debreceni Egyetem Klinikai Központ; Bőrgyógyászati Klinika, Debrecen, Hungary|Pecsi Tudomanyegyetem, Pecs, Hungary|Rambam Health Care Campus, Haifa, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Chaim Sheba Medical Center; Allergy and Clinical Immunology Unit, Ramat Gan, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, Italy|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Maastricht University Medical Center, Maastricht, Netherlands|Auckland City Hospital, Auckland, New Zealand|Christchurch Clinical Studies Trust, Christchurch, New Zealand|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Medisprof SRL, Cluj-Napoca, Romania|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin""; Chemotherapy Departement, Moskva, Moskovskaja Oblast, Russian Federation|Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic, Kazan, Russian Federation|SBIH "" Clinical Oncological Dispensary # 1""; Chemotherapy department #1 and #2, Krasnodar, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|St. Petersburg SHI ""City Clinical Oncology Dispensary"", Saint-Petersburg, Russian Federation|SBIH Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, Russian Federation|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, Serbia|Clinical Center Bezanijska Kosa, Belgrade, Serbia|Cape Town Oncology Trials, Cape Town, South Africa|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg, South Africa|Cancercare Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, LA Coruña, Spain|Hospital Regional Universitario de Malaga; Oncologia, Málaga, Malaga, Spain|Hospital General Universitario Santa Lucia, Cartagena (Murcia), Murcia, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Royal Marsden Hospital, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT01739764
Completed,Relapsing Remitting Multiple Sclerosis RRMS,Drug: Fingolimod,Novartis Pharmaceuticals|Novartis,87,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,20-Aug-12,2-Mar-20,"Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Zuerich, Switzerland",https://ClinicalTrials.gov/show/NCT01705236
Completed,Neoplasms,Drug: Bevacizumab,Hoffmann-La Roche,95,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-Jul-12,5-Nov-20,"A.Ö. LKH; Abt. für Lungenkrankheiten, Steyr, Austria|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital de Cancer de Barretos, Barretos, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, Brazil|Hospital Sao Jose, São Paulo, SP, Brazil|MBAL Serdika EOOD, Sofia, Bulgaria|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|North Estonia Medical Centre Foundation; Oncology Center, Tallinn, Estonia|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Centre Leonard De Vinci;Chimiotherapie, Dechy, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|Hopital Roger Salengro; Service de Neurologie, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Centre Paul Strauss; Oncologie Medicale, Strasbourg, France|Hopital Larrey; Pneumologie, Toulouse, France|Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main, Germany|LungenClinic Großhansdorf GmbH, Großhansdorf, Germany|Orszagos Onkologiai Intezet; Nogyogyaszati Osztaly, Budapest, Hungary|A.O. Universitaria Federico II Di Napoli; Oncologia Ed Endocrinologia Clinica, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1, Roma, Lazio, Italy|Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, Italy|ASST DI MONZA; Oncologia Medica, Monza, Lombardia, Italy|ASST LARIANA; Oncologia, S. Fermo Della Battaglia (CO), Lombardia, Italy|Azienda Ospedaliera Le Molintte di Torino; Dipartimento Di Neurologia - Oncologia, Torino, Piemonte, Italy|Ospedale Antonio Perrino; Oncologia Medica, Brindisi, Puglia, Italy|Centro Catanese Di Oncologia; Oncologia Medica, Catania, Sicilia, Italy|Ospedale Nuovo Della Versilia; Divisione Di Oncologia Medica, Lido Di Camaiore, Toscana, Italy|A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii, Pisa, Toscana, Italy|Ospedale Misericordia E Dolce; Oncologia Medica, Prato, Toscana, Italy|National Cancer Center; Medical Oncology, Gyeonggi-do, Korea, Republic of|Severance Hospital; Internal Medicine, Seoul, Korea, Republic of|Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology, Seoul, Korea, Republic of|Instituto Nacional de Cancerologia; Oncology, Distrito Federal, Mexico|Fundación Rodolfo Padilla Padilla, A.C.; Oncology, Leon, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Leyenburg Hospital; Pulmonology, Den Haag, Netherlands|Radboud Ziekenhuis; Urologie, 659, Nijmegen, Netherlands|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Euroclinic Center of Oncology SRL, Iasi, Romania|Altai Region Oncology Dispensory; Oncology, Barnaul, Russian Federation|Regional Oncology Hospital; Oncology, Irkutsk, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|Russian Research Center of Roentgenoradiology; Dept of Chemotherapy, Moscow, Russian Federation|P.A. Gertsen Cancer Research Inst. ; Chemotherapy Dept, Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|Medical Radiological Scientific Center; Department of Radiotherapy of Gynaecological Disease, Obninsk, Kaluzhskaya Region, Russian Federation|Bashkirian Republican Clinical Oncology Dispensary, UFA, Russian Federation|Vychodoslovensky onkologicky ustav, Košice, Slovakia|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg, South Africa|Hospital de Basurto; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital de Cruces; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Complejo Asistencial Universitario De Burgos; Servicio de Oncologia, Burgos, Spain|Hospital Reina Sofia; Medical Oncology, Cordoba, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, Spain|Hospital Gregorio Marañon, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Mälarsjukhuset, Eskilstuna, Kvinnokliniken, Eskilstuna, Sweden|Norrlands universitetssjukhus; Onkologkliniken, Umeå, Sweden|Universitetssjukhuset Örebro, Onkologiska kliniken, Örebro, Sweden|Adana City Hospital, Medical Oncology, Adana, Turkey|Addenbrooke'S Hospital; Dept of Neurosurgery, Cambridge, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, United Kingdom",https://ClinicalTrials.gov/show/NCT01588184
Completed,Age-Related Macular Degeneration|Retinal Vein Occlusion|Diabetic Macular Edema,Drug: pegaptanib sodium injection,Bausch & Lomb Incorporated,131,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,22-Apr-10,14-Oct-20,"Marietta Eye Clinic, Murrieta, California, United States|Wolfe Eye Clinic, Marshalltown, Iowa, United States|Associates in Ophthalmology, West Mifflin, Pennsylvania, United States|Valley Retina Institute, Harlingen, Texas, United States",https://ClinicalTrials.gov/show/NCT01573572
Terminated,Atrial Fibrillation,Device: Catheter Ablation|Drug: Drug Treatment,"Biosense Webster, Inc.",255,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-Feb-12,14-May-20,"Royal Adelaide Hospital, Adelaide, Australia|Medizinische Universitaetsklinik, Graz, Austria|Krankenhaus der Elisabethinen, Linz, Austria|OLV Ziekenhuis, Aalst, Belgium|AZ Sint Jan, Brugge, Belgium|Kerckhoff Klinik, Bad Nauheim, Germany|Vivantes Klinikum am Urban, Berlin, Germany|Helios Klinikum Berlin-Buch, Berlin, Germany|Herzzentrum Universitätsmedizin Göttingen, Göttingen, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|University Heart Center Hamburg-Eppendorf, Hamburg, Germany|Herzpraxis Altona, Hamburg, Germany|Semmelweis University, Cardiovascular Center, Budapest, Hungary|Mater Misericordiae University Hospital, Dublin, Ireland|Ospedale Generale Regionale ""F. Miulli"", Bari, Italy|Ospedaleria Universitaria Pisana, Pisa, Italy|Policlinico Casalino Roma, Roma, Italy|Korea University Anam Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|P. Stradins Clinical University Hospital, Riga, Latvia|Haukeland Universitetssykehus, Bergen, Norway|Cardinal Stefan Wyszyński Institute of Cardiology, Warszaw, Poland|Federal Center of Cardiovascular Surgery, Krasnoyarsk, Russian Federation|Federal State Institution National Research Center for Preventive Medicine of Healthcare of the Russian Federation, Moscow, Russian Federation|State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation|Almazov Federal Heart, Blood and Endocrinology Centre, Saint-Petersburg, Russian Federation|Federal State Budgetary Scientific Institution ""Research Institute for Cardiology"", Tomsk, Russian Federation|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Universitetssjukhuset Örebro, Örebro, Sweden|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Papworth Hospital, Cambridge, United Kingdom|University Hospital of South Manchester, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT01570361
Completed,Ischemic Stroke,Drug: intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|Device: Penumbra System,Penumbra Inc.,108,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,May-12,22-Sep-20,"Endovascular Surgical Neuroradiology, Swedish Medical Center, Denver, Colorado, United States|Department of Neurological Surgery, Gainesville, Florida, United States|Neurosurgery, Rush University Medical Center, Chicago, Illinois, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT01429350
Completed,Breast Neoplasms,Drug: Aromasin (exemestane),Pfizer,564,Masking: None (Open Label),9-Feb-11,12-Oct-20,"The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department, Bengbu, Anhui, China|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|The Second Hospital of Anhui Medical University, Hefei, Anhui, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|The First hospital of LanZhou university, Lanzhou, Gansu, China|Breast Surgery of The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|SUN YAT-SEN Memorial Hospital , SUN YAT-SEN University, Guangzhou, Guangdong, China|Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China|Thyroid and breast surgery, Shenzhen City, Guangdong, China|Affiliated hospital of Guangdong medical college, ZhanJiang, Guangdong, China|Hainan General Hospital, Haikou, Hainan, China|Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Henan provincial people's hospital, Zhengzhou, Henan, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Jingzhou Hospital Tongji Medical College Huazhong university of science and Technology, Jingzhou, Hubei, China|Breast and thyroid surgery of the Central Hospital of WuHan, WuHan, Hubei, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|Xiangya Hospital Central South University /Department of Breast, Changsha, Hunan, China|The Affiliated Hospital of inner Mongolia medical university, Hu He Hao Te, Inner Mongolia, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|Jiangsu Cancer Hospital/ Surgery Department, Nanjing, Jiangsu, China|Jinling Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital/ Surgery Department, Nanjing, Jiangsu, China|Nanjing Maternity and Child Health Care Hospital/Department of Breast Surgery, Nanjing, Jiangsu, China|Suzhou Municipal Hospital, Suzhou, Jiangsu, China|The first hospital of jilin university, Changchun, Jilin, China|The Fourth Affiliated Hospital Of China Medical University, ShenYang, Liaoning, China|The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shaanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Linyi People's Hospital, Linyi, Shandong, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|Qingdao municipal Hospital, Qingdao, Shandong, China|Breast Surgery of The Weifang People's Hospital, Weifang, Shandong, China|Breast Surgery of YanTai Yu Huang Ding Hospital, Yan Tai, Shandong, China|Breast and thyroid surgery of Central Hospital of Zibo, Zibo, Shandong, China|West China Hospital, Sichuan University/ Oncology Department, Chengdu, Sichuan, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China|Tianjin Cancer Hospital/Breast cancer department, Tianjin, Tianjin, China|Affiliated Cancer Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China|Yunnan Cancer Hospital, Kunming, Yunnan, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Cancer Hospital Chinese Academy of medical sciences, Beijing, China|Fifth Medical Center of the PLA General Hospital, Beijing, China|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital/Department of Oncology, Beijing, China|China-Japan Friendship Hospital, Beijing, China|Fudan University Shanghai Cancer center/Department of Breast Surgery, Shanghai, China|Yangpu District Central Hospital, Shanghai, China|Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China",https://ClinicalTrials.gov/show/NCT01176916
Completed,Metastatic Castration-resistant Prostate Cancer (mCRPC),Drug: Enzalutamide,"Astellas Pharma Global Development, Inc.|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.|Astellas Pharma Inc",424,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,25-Sep-13,9-Dec-20,"Site US10005, Anchorage, Alaska, United States|Site US10024, Detroit, Michigan, United States|Site US10026, Bronx, New York, United States|Site US10001, New York, New York, United States|Site US10014, New York, New York, United States|Site US10039, Syracuse, New York, United States|Site US10016, Durham, North Carolina, United States|Site US10008, Dallas, Texas, United States|Site US10025, Seattle, Washington, United States|Site AR54001, Berazategui, Buenos Aires, Argentina|Site AR54006, Ciudad Autonoma de BuenosAires, Buenos Aires, Argentina|Site AR54002, Buenos Aires, Caba, Argentina|Site AR54003, Cordoba, Argentina|Site AR54004, Santa Fe, Argentina|Site AR54005, Tucuman, Argentina|Site AU61012, Kogarah, New South Wales, Australia|Site AU61005, Randwick, New South Wales, Australia|Site AU61011, Sydney, New South Wales, Australia|Site AU61001, Tweed Heads, New South Wales, Australia|Site AU61002, Nambour, Queensland, Australia|Site AU61007, Adelaide, South Australia, Australia|Site AU61004, Ballarat, Victoria, Australia|Site BE32004, Anderlecht, Belgium|Site BE32001, Kortrijk, Belgium|Site BE32003, Liege, Belgium|Site CA15005, Abbotsford, British Columbia, Canada|Site CA15014, Halifax, Nova Scotia, Canada|Site CA15004, Brampton, Ontario, Canada|Site CA15010, Scarborough, Ontario, Canada|Site CA15001, Quebec City, Quebec, Canada|Site CL56001, Temuco, IX Region, Chile|Site CL56004, Santiago, Chile|Site CL56002, Temuco, Chile|Site CL56003, Vina del Mar, Chile|Site CZ42004, Praha 2, Czechia|Site CZ42002, Praha 6, Czechia|Site FI35803, Helsinki, Finland|Site FI35801, Oulu, Finland|Site FI35802, Tampere, Finland|Site FR33002, Lyon Cedex 03, France|Site FR33004, Rouen Cedex, France|Site FR33005, Suresnes, France|Site DE49009, Nürtingen, Baden-Württemberg, Germany|Site DE49003, Berlin, Germany|Site DE49001, Munster, Germany|Site HU36002, Sopron, Gyor-Moson Sopron, Hungary|Site IL97202, Kfar Saba, HaMerkaz, Israel|Site IL97201, Be'er Ya'akov, Israel|Site IL97203, Beer-Sheva, Israel|Site IL97205, Haifa, Israel|Site IL97204, Jerusalem, Israel|Site IL97208, Nahariya, Israel|Site IL97206, Petah-Tiqva, Israel|Site IL97207, Ramat Gan, Israel|Site IT39005, Meldola, Emilia-Romagna, Italy|Site IT39001, Cremona, Lombardia, Italy|Site IT39002, Arezzo, Italy|Site IT39003, Roma, Italy|Site KR82006, Seongnam-Si, Gyeonggi-do, Korea, Republic of|Site KR82007, Seoul, Korea, Republic of|Site KR82003, Seoul, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|Site KR82004, Seoul, Korea, Republic of|Site NZ64001, Hamilton, New Zealand|Site SG65002, Singapore, Singapore|Site ES34007, Hospitalet de Llobregat, Barcelona, Spain|Site ES34005, Sabadell, Barcelona, Spain|Site ES34001, Pamplona, Navarra, Spain|Site ES34003, Barcelona, Spain|Site ES34004, Barcelona, Spain|Site ES34006, Madrid, Spain|Site SE46001, Goteborg, Sweden|Site SE46002, Orebro, Sweden|Site TW88601, Kaohsiung, Taiwan|Site TW88603, Taipei City, Taiwan|Site GB44002, Sutton, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT01977651
Completed,"Epilepsy, Partial",Drug: Levetiracetam,UCB Pharma,251,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,24-Nov-03,19-Aug-20,"N01036 808, Hong Kong, Hong Kong|N01036 842, Hong Kong, Hong Kong|N01036 815, Kwun Tong, Hong Kong|N01036 811, Kuala Lumpur, Malaysia|N01036 812, Kuala Lumpur, Malaysia|N01036 813, Kuala Lumpur, Malaysia|N01036 830, Manila, Philippines|N01036 831, Manila, Philippines|N01036 829, Quezon, Philippines|N01036 804, Singapore, Singapore|N01036 806, Singapore, Singapore|N01036 807, Singapore, Singapore|N01036 828, Changhua, Taiwan|N01036 827, Hualien City, Taiwan|N01036 825, Kaohsiung City, Taiwan|N01036 834, Kaohsiung, Taiwan|N01036 835, Kaohsiung, Taiwan|N01036 823, Taichung city, Taiwan|N01036 817, Taichung, Taiwan|N01036 818, Tainan, Taiwan|N01036 819, Taipei, Taiwan|N01036 820, Taipei, Taiwan|N01036 821, Taipei, Taiwan|N01036 822, Taoyuan, Taiwan|N01036 809, Bangkok, Thailand|N01036 840, Bangkok, Thailand|N01036 841, Bangkok, Thailand|N01036 839, Chiang Mai, Thailand|N01036 810, Khon Kaen, Thailand",https://ClinicalTrials.gov/show/NCT00160654
Completed,Constipation,"Drug: Polyethylene glycol (MiraLAX, BAY81-8430)|Drug: Mannitol",Bayer,50,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-Feb-13,12-Nov-20,"Merck Consumer Center, Memphis, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04534465
Completed,"Carcinoma, Non-Small-Cell Lung|ErbB Receptors",Drug: Afatinib,Boehringer Ingelheim,25,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-Aug-15,30-Mar-20,"Mayo Clinic-Arizona, Scottsdale, Arizona, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|City of Hope, Duarte, California, United States|Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|University of Miami, Miami, Florida, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Baystate Health D'Amour Center for Cancer Care, Springfield, Massachusetts, United States|Montefiore Medical Center, Bronx, New York, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT02514174
Completed,"Spondylitis, Ankylosing",Biological: Etanercept,Pfizer,210,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,24-Sep-15,16-Jun-20,"Gulf Region Clinical Research Institute, Pensacola, Florida, United States|Northwestern Medical Group; Division of Rheumatology, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Northwestern University Clinical and Translational Sciences Institute (NUCATS), Chicago, Illinois, United States|Winthrop University Hospital, Clinical Trials Center, Mineola, New York, United States|Oregon Health and Science University Research Pharmacy, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Swedish Medical Center Investigational Drug Services Pharmacy, Seattle, Washington, United States|Seattle Rheumatology Associates, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|Genesis Research Services Pty Ltd, Broadmeadow, New South Wales, Australia|Hunter Imaging Group, Cardiff, New South Wales, Australia|Pacific Radiology, Maroochydore, Queensland, Australia|Rheumatology Research Centre, Maroochydore, Queensland, Australia|Benson Radiology, North Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|SKG Radiology Hollywood Hospital, Nedlands, Western Australia, Australia|SKG Radiology Subiaco, Subiaco, Western Australia, Australia|R.K. Will Pty Ltd, Victoria Park, Western Australia, Australia|Private Practice Rheumatology, Sint-Niklaas, OVL, Belgium|Reumaclinic, Genk, Belgium|Centro Integral de Reumatologia Reumalab S.A.S., Medellin, Antioquia, Colombia|Hospital Pablo Tobon Uribe, Medellin, Antioquia, Colombia|Preventive Care SAS, Chía, Cundinamarca, Colombia|Affidea Praha s.r.o., Praha 11, Czechia|Revmatologicky ustav, Praha 2, Czechia|MEDICAL PLUS, s.r.o., Uherske Hradiste, Czechia|Uherskohradist' ska nemocnice a.s., Uherske Hradiste, Czechia|Lekarna Hradebni s.r.o., Uherske Hradiste, Czechia|Helsinki University Hospital, Helsinki, Finland|HYKS, Meilahden kolmiosairaala, Helsinki, Finland|Kiljavan Laaketutkimus Oy, Hyvinkaa, Finland|Service d'Imagerie Guilloz, Nancy, France|Hopital Cochin Pavillon Hardy B4, Paris, France|Pharmacie-Secteur Essais cliniques, Paris, France|CHU de Rennes, Hopital Sud, Rennes, France|CHU PURPAN, Hopital Pierre-Paul Riquet, Toulouse cedex 9, France|Pharmacie, Toulouse cedex 9, France|Pharmacie Essais cliniques, Vandoeuvre les Nancy, France|CHU de Nancy - Hopital de Brabois, Vandoeuvre-les-Nancy cedex, France|Medizinische Klinik und Poliklinik IV, Muenchen, Bavaria, Germany|Rheumazentrum Ruhrgebiet, Herne, NRW, Germany|Charité Universitaetsmedizin Berlin, Berlin, Germany|Apotheke am Tierpark, Berlin, Germany|Charité Universitaetsmedizin Berlin, Berlin, Germany|Praxis für radiologische Diagnostik, Berlin, Germany|Rheumatologische Schwerpunktpraxis, Berlin, Germany|Schlosspark-Klinik GmbH, Berlin, Germany|Mvz Agilomed, Chemnitz, Germany|Universitaetskliniken Koeln, Koeln, Germany|Qualiclinic Kft., Budapest, Hungary|VITAL MEDICAL CENTER Orvosi es Fogorvosi Kozpont, Veszprem, Hungary|READE, Amsterdam, Netherlands|LUMC, Leiden, Netherlands|Nzoz McD Voxel, Bydgoszcz, Poland|Szpital Uniwersytecki nr 2 im. dr J. Biziela w Bydgoszczy, Klinika Reumatologii i Ukladowych Chorob, Bydgoszcz, Poland|Zaklad Radiologii i Diagnostyki Obrazowej, Bydgoszcz, Poland|Centrum Kliniczno-Badawcze J. Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska, Elblag, Poland|Samodzielny Publiczny Zespol Opieki Zdrowotnej, Koscian, Poland|Reumed Sp z.o.o. Zespool Poradni Specjalistycznych Filia nr 1, Lublin, Poland|RCMed, Nowy Duninow, Poland|Diagnostic-Med Centrum Diagnostyki Radiologicznej, Poznan, Poland|RCMed, Sochaczew, Poland|SANUS Szpital Specjalistyczny Sp. z o.o., Stalowa Wola, Poland|Nasz Lekarz Przychodnie Medyczne, Torun, Poland|Medycyna Kliniczna, Warszawa, Poland|Reumatika-Centrum Reumatologii NZOZ, Warszawa, Poland|Centrum Medyczne OPOROW, Wrocław, Poland|Complejo Hospitalario Universitario Santiago, Santiago de Compostela, A Coruna, Spain|Hospital Universitario de Canarias, San Cristobal de la Laguna, Santa CRUZ DE Tenerife, Spain|Complexo Hospitalario Universitario A Coruna, La Coruna, Spain|Hospital San Rafael, La Coruna, Spain|Complejo Hospitalario Regional Virgen Macarena, Sevilla, Spain|Sahlgrenska University Hospital, Gothenburg, Sweden|Skanes University Hospital Malmo, Malmo, Sweden|Akademiska sjukhuset, Uppsala, Sweden|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Chung Shan Medical University, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan",https://ClinicalTrials.gov/show/NCT02509026
Completed,Pulmonary Arterial Hypertension,Drug: Macitentan,Actelion,89,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Jun-15,24-Sep-20,"Massachussetts General Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Rudgers New Jersey Medical School, New Brunswick, New Jersey, United States|Cornell University, New York, New York, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical, Dallas, Texas, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|The Prince Charles Hospital, Chermside, Queensland, Australia|Hopital Gabriel Montpied, Clermont-Ferrand, France|Hôpital Michallon, La Tronche, France|""CHRU de Lille - Hôpital Albert Calmette "", Lille Cedex, France|Hopital de Brabois, Nancy, France|Hôpital Laennec, Nantes Cedex 01, France|Hôpital Pasteur, Nice, France|Hôpital Européen Georges-Pompidou, Paris, France|Medizinische Klinik und Poliklinik II Universitätsklinik Bonn, Bonn, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin, Köln, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz Centrum für Thrombose und Hämostase, Mainz, Germany|Grantham Hospital, Cardiac Medical Unit, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|United Christian Hospital, Hong Kong, Hong Kong|Pulmonology institute, Soroka Medical Center, Beer-Sheva, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Fondazione IRCCS Policlinico San Matteo Ambulatorio Scompenso Cardiaco e Trapianti, Pavia, Italy|Hospital Pulau Pinang, George Town, Malaysia|Institut Jantung Negara (National Heart Institute), Kuala Lumpur, Malaysia|VU University Medical Center (VUMC), Amsterdam, Netherlands|Maastricht UMC+, Maastricht, Netherlands|St. Antonius Ziekenhuis, Nieuwegein, Netherlands|Radboud UMC, Nijmegen, Netherlands|Erasmus University medical Center, Rotterdam, Netherlands|Russian Cardiology Scientific and Production Complex, Moscow, Russian Federation|Almazov Federal North-West Medical Research Centre of Department of Health, Saint Petersburg, Russian Federation|National University Hospital - The Heart Institute - Cardiac Department, Singapore, Singapore|National Heart Centre (NHC) Singapore, Singapore, Singapore|Golden Jubilee National Hospital, Glasgow, United Kingdom|The Royal Free Hospital, London, United Kingdom|""Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital"", Sheffield, United Kingdom",https://ClinicalTrials.gov/show/NCT02310672
Completed,Diabetic Foot Ulcer,Biological: GrafixPL PRIME,University of Texas Southwestern Medical Center|Osiris Therapeutics,40,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-Nov-18,30-Jul-20,"UT Southwestern Medical Center at Dallas, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT03742440
Terminated,Chronic Pain|Opioid Use|Deglutition,Drug: Xtampza ER (oxycodone),"Ajay Wasan, MD, Msc|Collegium Pharmaceutical, Inc.|University of Pittsburgh",11,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,1-May-18,4-Jun-20,"UPMC Pain Medicine at Centre Commons, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT03588806
Terminated,Cervical Cancer|Uterine Cancer,Drug: 18F fluciclovine|Device: 18F fluciclovine PET,Nghi Nguyen|Blue Earth Diagnostics|University of Pittsburgh,1,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,11-Dec-18,28-Oct-20,"UPMC Presbyterian - MR Research Center, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT03423082
Completed,Hepatitis C,Drug: EBR/GZR,National Taiwan University Hospital|Merck Sharp & Dohme Corp.,40,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5-Jun-18,11-Mar-20,"National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Far Eastern Memorial Hospital, Taipei county, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Medical University, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT03420300
Completed,Dry Eye Disease,Drug: Corticotropin 80Unit/Ml Repository Injection,Toyos Clinic|Mallinckrodt,19,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Jul-18,28-Jan-21,"Toyos Clinic, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT03287635
Completed,Tooth Loss,Drug: Alveolar Ridge Reconstruction,"Gustavo Avila-Ortiz DDS, MS, PhD|Osteogenics Biomedical|University of Iowa",17,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Mar-17,22-Jan-20,"University of Iowa College of Dentistry - Craniofacial Clinical Research Program, Iowa City, Iowa, United States",https://ClinicalTrials.gov/show/NCT02980211
Terminated,"Kidney Transplant Rejection|Gastrointestinal Disorder, Functional",Drug: Everolimus|Drug: Mycophenolic Acid,Washington University School of Medicine|Novartis Pharmaceuticals,1,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Nov-16,10-Aug-20,"Washington University, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT02974686
Completed,Renal Failure,Drug: elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination),Massachusetts General Hospital|Merck Sharp & Dohme Corp.,8,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1-Feb-17,26-Feb-20,"Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT02945150
Completed,Atrial Fibrillation|End Stage Renal Disease,Drug: apixaban|Drug: warfarin,"Christopher Granger, MD|Bristol-Myers Squibb|Duke University",154,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Dec-16,29-Dec-20,"Nephrology Consultants, Huntsville, Alabama, United States|The Medical Research Group, Inc., Fresno, California, United States|DaVita Clinical Trials, LLC, Long Beach, California, United States|Southland Renal Medical Group, Long Beach, California, United States|Valley Renal Medical Group Research, Northridge, California, United States|Summit Nephrology Medical Group, Inc., Roseville, California, United States|Satellite Healthcare, San Jose, California, United States|Washington Nephrology Associates, Washington, District of Columbia, United States|South Florida Nephrology Group PA, Research Division, Coral Springs, Florida, United States|LG. Diagnostic, Inc. & Cosmetic Center, Miami, Florida, United States|Nuren Medical and Research Center, Miami, Florida, United States|Medical Professional Clinical Research Center, Miami, Florida, United States|Boise Kidney and Hypertension Institute, Meridian, Idaho, United States|Northwestern University, Chicago, Illinois, United States|NANI Research, Crystal Lake, Illinois, United States|NANI Research, River Forest, Illinois, United States|NANI Research, Fort Wayne, Indiana, United States|Northwest Louisiana Nephrology, Shreveport, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Washington Nephrology Associates, Takoma Park, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|South Shore Nephrology, Plymouth, Massachusetts, United States|Renal and Transplant Associates of New England, Springfield, Massachusetts, United States|Paragon Health Neprhology Centre, Kalamazoo, Michigan, United States|St. Clair Nephrology, Port Huron, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Southwest Mississippi Nephrology, PLLC, Brookhaven, Mississippi, United States|Southern Clinical Research Group, LLC, Gulfport, Mississippi, United States|Nephrology & Hypertension Associates, Tupelo, Mississippi, United States|Polack Renal, LLC, Saint Louis, Missouri, United States|Sierra Nevada Nephrology Consultants, Reno, Nevada, United States|Renal Medicine Associates, Albuquerque, New Mexico, United States|Advanced Kidney Care of Hudson Valley, Poughkeepsie, New York, United States|Durham Nephrology Associates, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Eastern Nephrology Associates, PLLC., Kinston, North Carolina, United States|Eastern Nephrology Associates, PLLC, New Bern, North Carolina, United States|HNC Dialysis, Ltd., Columbus, Ohio, United States|Northeast Clinical Research Ctr, Bethlehem, Pennsylvania, United States|Penn State Health - Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Columbia Nephrology Associates, Columbia, South Carolina, United States|South Carolina Nephrology and Hypertension, Orangeburg, South Carolina, United States|Sumter Medical Specialists, Sumter, South Carolina, United States|Regional Health Clinical Research, Rapid City, South Dakota, United States|Knoxville Kidney Center, Knoxville, Tennessee, United States|Southwest Houston Research, Ltd., Houston, Texas, United States|Lubbock Vascular Access Center, Lubbock, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Washington Nephrology Associates, Alexandria, Virginia, United States|University of Virgina Health System, Charlottesville, Virginia, United States|TPMG Clinical Research, Newport News, Virginia, United States|Valley Nephrology Associates, Roanoke, Virginia, United States|University of Washington, Seattle, Washington, United States|Nephrology and Hypertension Associates, Bluefield, West Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Aspirius Research Institute, Wausau, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT02942407
Completed,"Hepatitis C, Chronic|Heart Failure|Pulmonary Disease, Chronic Obstructive|Lung Diseases, Interstitial",Drug: Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC),Duke University|Gilead Sciences,15,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Dec-16,21-Apr-20,"Henry Ford Health System, Detroit, Michigan, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center - Dept of Gastroenterology, Durham, North Carolina, United States|Harborview Medical Center, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT02858180
Completed,Nonproliferative Diabetic Retinopathy,Drug: Lucentis,Wonkwang University Hospital|Novartis Korea Ltd.,25,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,Aug-16,22-Apr-20,,https://ClinicalTrials.gov/show/NCT02834663
Completed,Chronic Obstructive Pulmonary Disease|Asthma|Pneumococcal Infections,Biological: Prevenar-13|Biological: Pneumo-23,Mikhael Petrovich Kostinov|Pfizer|Russian Academy of Medical Sciences,219,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6-Sep-12,25-Feb-20,"Samara State Medical Univercity, Samara, Samara Region, Russian Federation|Institute of Sera and Vaccines RAS, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT02787863
Completed,Atrial Fibrillation,Drug: Interrupted apixaban|Drug: Uninterrupted apixaban,Baim Institute for Clinical Research|Bristol-Myers Squibb,300,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Nov-15,17-Mar-20,"Site 0020, Huntsville, Alabama, United States|Site 0005, Mission Viejo, California, United States|Site 0012, New Haven, Connecticut, United States|Site 0011, Trumbull, Connecticut, United States|Site 0016, Pensacola, Florida, United States|Site 0014, West Des Moines, Iowa, United States|Site 0018, Bangor, Maine, United States|Site 0004, Scarborough, Maine, United States|Site 0008, Boston, Massachusetts, United States|Site 0001, Burlington, Massachusetts, United States|Site 0006, Kansas City, Missouri, United States|Site 0021, Omaha, Nebraska, United States|Site 0019, Albuquerque, New Mexico, United States|Site 0002, Toledo, Ohio, United States|Site 0007, Oklahoma City, Oklahoma, United States|Site 0009, Philadelphia, Pennsylvania, United States|Site 0010, Charleston, South Carolina, United States|Site 0017, Austin, Texas, United States|Site 0003, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT02608099
Completed,Psoriasis,Drug: Secukinumab,"University of California, San Francisco|Novartis Pharmaceuticals",15,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Oct-16,27-Aug-20,"UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT02592018
Completed,"Heart Failure, Diastolic|Diastolic Heart Failure|Hypertension",Drug: regadenoson,"Marvin W. Kronenberg, M.D.|Astellas Pharma US, Inc.|Vanderbilt University Medical Center",55,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Nov-15,2-Feb-21,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT02589977
Completed,Ankle Arthrodesis|Hindfoot Arthrodesis|Tibitalocalceal Arthrodesis,Drug: Exparel,"OrthoCarolina Research Institute, Inc.|Pacira Pharmaceuticals, Inc",36,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Feb-14,29-Oct-20,"OrthoCarolina, PA, Charlotte, North Carolina, United States",https://ClinicalTrials.gov/show/NCT02586077
Terminated,Atrial Fibrillation,Drug: Edoxaban|Drug: Warfarin,Electrophysiology Research Foundation|Axio Research Corporation,5,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Dec-15,10-Feb-20,"Electrophysiology Research Foundation, Warren, New Jersey, United States",https://ClinicalTrials.gov/show/NCT02561897
Completed,Type 2 Diabetes Mellitus,Drug: insulin glargine|Drug: metformin|Drug: Forxiga|Behavioral: Lifestyle therapy,Population Health Research Institute|AstraZeneca,154,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Dec-15,24-Nov-20,"University of Calgary, Calgary, Alberta, Canada|Health Science Centre, Winnipeg, Manitoba, Canada|McMaster University, Hamilton, Ontario, Canada|St. Joseph's Hospital, London, Ontario, Canada|Western University, London, Ontario, Canada|LMC, Toronto, Ontario, Canada|St. Michaels's Hospital, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT02561130
Completed,Myocardial Infarction|Diabetes Mellitus|Peripheral Arterial Disease,Drug: Vorapaxar|Drug: Clopidogrel|Drug: Aspirin,University of Florida|Merck Sharp & Dohme Corp.,66,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,25-Mar-16,27-Jan-20,"University of Florida, Jacksonville, Florida, United States",https://ClinicalTrials.gov/show/NCT02548650
Completed,Myocardial Infarction,Drug: Prasugrel|Drug: Vorapaxar|Drug: Aspirin|Drug: Ticagrelor,University of Florida|Merck Sharp & Dohme Corp.,130,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Feb-16,25-Aug-20,"University of Florida, Jacksonville, Florida, United States",https://ClinicalTrials.gov/show/NCT02545933
Completed,Retinal Vein Occlusion|Diabetic Macular Edema|Branch Retinal Vein Occlusion|Central Retinal Vein Occlusion,Drug: Aflibercept,Justis Ehlers|Regeneron Pharmaceuticals|The Cleveland Clinic,31,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-Aug-15,12-Feb-20,"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT02503540
Completed,Overactive Bladder,Drug: Mirabegron,"Loyola University|Astellas Pharma US, Inc.",84,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28-Jan-15,13-Nov-20,"Loyola University Medical Center, Maywood, Illinois, United States",https://ClinicalTrials.gov/show/NCT02495389
Completed,"Hepatitis C, Chronic","Drug: ombitasvir, paritaprevir/r, dasabuvir + ribavirin|Drug: ombitasvir, paritaprevir/r, dasabuvir",Kaiser Permanente|AbbVie,200,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Jun-15,22-Jan-21,"Kaiser Permanente Medical Center, Irvine, California, United States|Kaiser Permanente Medical Center, Los Angeles, California, United States|Kaiser Permanente Medical Center, San Diego, California, United States|Kaiser Permanente Medical Center, San Marcos, California, United States",https://ClinicalTrials.gov/show/NCT02461745
Terminated,Multiple Sclerosis,Drug: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®),Weill Medical College of Cornell University|Mallinckrodt,15,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Jun-16,22-Jan-21,"Weill Cornell Medicine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT02446886
Completed,Cardiac Diagnostic Procedure|Cardiac Interventional Procedure|Femoral Access Site Closure,Device: Mynx Vascular Closure System|Other: Manual Compression,Medstar Health Research Institute|Cardinal Health,208,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Jun-15,18-Nov-20,"MedStar Washington Hospital Center, Washington, District of Columbia, United States|MedStar Southern Maryland Hospital, Clinton, Maryland, United States",https://ClinicalTrials.gov/show/NCT02438475
Completed,Primary Biliary Cirrhosis,Biological: abatacept,"Christopher Bowlus, MD|Bristol-Myers Squibb|University of California, Davis",16,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sep-14,30-Mar-20,"Univeristy of California Davis Medical Center, Sacramento, California, United States",https://ClinicalTrials.gov/show/NCT02078882
Terminated,Proteinuria|Transplant Glomerulopathy,Drug: Acthar,University of Illinois at Chicago|Mallinckrodt,2,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sep-14,4-Sep-20,"University of Illinois at Chicago, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT02057523
Completed,Knee Osteoarthritis,Drug: Euflexxa|Device: Magnetic Resonance Imaging (MRI),"University of California, San Francisco|Ferring Pharmaceuticals",12,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Aug-13,18-Nov-20,"UCSF - China Basin Imaging Center, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT01895959
Completed,Chronic Obstructive Lung Disease,Drug: Symbicort® total dose 400ug/12ug|Drug: Symbicort® total dose 800ug/24ug|Drug: Formoterol 24ug|Drug: BUD total dose 800ug,Imperial College London|AstraZeneca,31,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Jan-13,23-Nov-20,"Royal Brompton and Harefield NHS trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT01787097
Completed,Chronic Urticaria,Drug: Omalizumab,"University of Colorado, Denver|Genentech, Inc.",10,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Apr-13,4-Dec-20,"University of Colorado Hospital, Denver, Colorado, United States",https://ClinicalTrials.gov/show/NCT01701583
Completed,Obesity|Nutrition Disorders|Overweight,Drug: Micafungin,"University of Texas Southwestern Medical Center|Astellas Pharma US, Inc.",36,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Nov-09,27-Nov-20,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT01090141
Completed,Systemic Sclerosis|Shortness of Breath|Pulmonary Hypertension,Drug: Ambrisentan,"University of California, Los Angeles|Gilead Sciences",12,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Mar-09,2-Nov-20,"David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT01051960
Completed,Major Depressive Disorder|Soft Tissue Discomfort Syndrome|Pain,Drug: Duloxetine,University of Pennsylvania|Eli Lilly and Company,22,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Apr-06,16-Apr-20,"Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT01035073
Completed,Type 2 Diabetes Mellitus,Drug: NPH/Regular 70/30 mix|Drug: insulin aspart protamine/insulin aspart 70/30 mix,"Dennis G. Karounos, M.D.|Novo Nordisk A/S|Lexington VA Medical Center",120,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-Mar-09,4-Mar-20,"VA Medical Center - Lexington 596, Lexington, Kentucky, United States",https://ClinicalTrials.gov/show/NCT00821795
Completed,Renal Transplantation,Drug: sirolimus,California Pacific Medical Center Research Institute|Novartis Pharmaceuticals,29,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,May-07,27-Oct-20,"California Pacific Medical Center; Barry S. Levin, MD Department of Transplantation, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT00713284
Terminated,HIV Infections,Drug: Once daily,Oklahoma State University Center for Health Sciences|Abbott,6,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,May-08,4-Dec-20,"OSU Internal Medicine Specialty Clinic, Tulsa, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT00679926
Completed,Gastrointestinal Symptoms|Heart Transplantation,Drug: Mycophenolate Sodium,Cedars-Sinai Medical Center|Novartis Pharmaceuticals,11,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Jun-06,8-Jul-20,"Cedars- Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT00574197
Completed,Infertility|Controlled Ovarian Hyperstimulation,Drug: COS with GnRH antagonists and rFSH|Drug: COS with GnRH antagonists and HP-HMG,"Instituto Valenciano de Infertilidad, IVI VALENCIA|Roche Pharma AG",112,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-Oct-16,3-Mar-20,"IVI Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT02738580
Completed,Influenza,"Biological: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation|Biological: Fluzone High-Dose vaccine, 2019-2020 formulation","Sanofi Pasteur, a Sanofi Company|Sanofi",90,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,30-Sep-19,17-Dec-20,"Investigational Site Number 8400002, Bardstown, Kentucky, United States|Investigational Site Number 8400001, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04109222
Completed,"Influenza, Human",Other: Passive enhanced safety surveillance,GlaxoSmithKline,1060,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,5-Oct-18,8-Apr-20,"GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Steenokkerzeel, Belgium|GSK Investigational Site, Tessenderlo, Belgium|GSK Investigational Site, Dachau, Bayern, Germany|GSK Investigational Site, Kuenzing, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Marbella - Málaga, Andalucia, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Sevilla, Spain",https://ClinicalTrials.gov/show/NCT03688620
Completed,Vulvovaginal Candidiasis,Drug: Terconazole Vaginal Suppository|Drug: Fluconazole,"Peking University Shenzhen Hospital|Shanghai Shyndec Pharmaceutical Co., Ltd.",140,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Aug-13,23-Oct-20,"Peking University Shenzhen Hosptal, Shenzhen, Guangdong, China",https://ClinicalTrials.gov/show/NCT02180100
Completed,Cystic Fibrosis,Drug: Placebo|Device: Tobi Podhaler,Mylan Inc.,47,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,26-Jun-18,30-Jun-20,"Batchelor Childrens Research Institute, Miami, Florida, United States|University of Miami Hospital, Miami, Florida, United States|Nemours Childrens Hospital, Orlando, Florida, United States|Nemour's Children's Clinic - Pensacola, Pensacola, Florida, United States|Tulane Lakeside Hospital for Women and Children, New Orleans, Louisiana, United States|Toledo Childrens Hospital, Toledo, Ohio, United States|University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States|Respiratory Diseases of Children and Adolescents, Oklahoma City, Oklahoma, United States|VCU Children's Pavilion, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT03502070
Completed,Congenital Bleeding Disorder|Haemophilia A,Drug: turoctocog alfa,Novo Nordisk A/S,60,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Mar-18,18-Mar-20,"Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Cochin, Kerala, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkatta, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India",https://ClinicalTrials.gov/show/NCT03449342
Completed,Homozygous Familial Hypercholesterolemia HoFH,Drug: evolocumab,Amgen,30,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4-Aug-18,3-Nov-20,"Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Belagavi, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Lucknow, Uttar Pradesh, India",https://ClinicalTrials.gov/show/NCT03403374
Completed,Primary Immunodeficiency,Drug: IgPro20,CSL Behring,49,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-Feb-17,13-Jan-20,"Clinical Research Center of Alabama, Birmingham, Alabama, United States|Research Solutions of Arizona, Litchfield Park, Arizona, United States|University of Southern Florida, Saint Petersburg, Florida, United States|Georgia Pollens Clinical Research Centers, Albany, Georgia, United States|Long Island Jewish Medical Center, Great Neck, New York, United States|Icahn Medical Institute, New York, New York, United States|Center for Clinical Research Rochester General Hospital, Rochester, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Duke University School of Medicine, Durham, North Carolina, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|The Ottawa Hospital, Ottawa, Ontario, Canada|McGill University, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT03033745
Completed,Epilepsy,Drug: Perampanel,Eisai Korea Inc.|Eisai Inc.,106,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3-May-16,5-Feb-20,"Busan, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Gwangju, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT02726074
Completed,Kidney Transplantation,Drug: Tacrolimus|Drug: Tacrolimus immediate release,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",599,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9-Sep-16,29-Jun-20,"Site US10006, Birmingham, Alabama, United States|Site US10025, Scottsdale, Arizona, United States|Site US10031, Los Angeles, California, United States|Site US10005, Sacramento, California, United States|Site US10016, San Francisco, California, United States|Site US10024, Aurora, Colorado, United States|Site US10003, New Haven, Connecticut, United States|Site US10014, Washington, District of Columbia, United States|Site US10030, Jacksonville, Florida, United States|Site US10020, Chicago, Illinois, United States|Site US10010, Chicago, Illinois, United States|Site US10001, Baltimore, Maryland, United States|Site US10007, Boston, Massachusetts, United States|Site US10013, Ann Arbor, Michigan, United States|Site US10032, Detroit, Michigan, United States|Site US10029, Minneapolis, Minnesota, United States|Site US10027, Rochester, Minnesota, United States|Site US10019, Livingston, New Jersey, United States|Site US10004, Buffalo, New York, United States|Site US10037, New York, New York, United States|Site US10022, New York, New York, United States|Site US10028, New York, New York, United States|Site US10021, Syracuse, New York, United States|Site US10026, Portland, Oregon, United States|Site US10002, Charleston, South Carolina, United States|Site US10036, Houston, Texas, United States|Site US10018, Salt Lake City, Utah, United States|Site US10012, Charlottesville, Virginia, United States|Site US10008, Falls Church, Virginia, United States|Site US10023, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT02723591
Completed,Depression|Quality of Life,Drug: Botulinum Toxin Type A,Brazilan Center for Studies in Dermatology|Allergan,50,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Oct-09,26-Jan-21,"Brazilian Center for Studies in Dermatology, Porto Alegre, Rio Grande Do Sul, Brazil",https://ClinicalTrials.gov/show/NCT01004042
Completed,Asthma,Drug: pMDI budesonide/formotrol 160/4.5 is in group 1|Device: Symbicort 160/4.5 plus Aerochamber Plus included in group 2,Western Sky Medical Research|AstraZeneca,16,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,Jul-09,13-Aug-20,"Western Sky Medical Research, El Paso, Texas, United States",https://ClinicalTrials.gov/show/NCT00915538
Terminated,HIV Infections,Drug: lopinavir/ritonavir plus maraviroc,Temple University|Abbott|Pfizer,1,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Apr-10,2-Nov-20,"Temple General Internal Medicine, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT01068873
Terminated,Pompe Disease|Glycogen Storage Disease Type II (GSD-II)|Glycogenesis 2 Acid Maltase Deficiency,Biological: Myozyme® (alglucosidase alfa),"Genzyme, a Sanofi Company|Sanofi",4,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-Dec-08,12-Oct-20,"Louisville, Kentucky, United States|Durham, North Carolina, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Haifa, Israel",https://ClinicalTrials.gov/show/NCT00701701
Completed,Parkinson Disease,Drug: Droxidopa|Drug: Carbidopa,Vanderbilt University Medical Center|H. Lundbeck A/S|American Academy of Neurology,15,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-Apr-17,27-Jan-20,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT03115827
Completed,Adverse Effects in the Therapeutic Use of Plasma Substitutes,Biological: Octaplas™,Octapharma,41,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Apr-15,24-Mar-20,"Octapharma Research Site, Birmingham, Alabama, United States|Octapharma Research Site, Atlanta, Georgia, United States|Octapharma Research Site, New Orleans, Louisiana, United States|Octapharma Research Site, Minneapolis, Minnesota, United States|Octapharma Research Site, Kansas City, Missouri, United States|Octapharma Research Site, Saint Louis, Missouri, United States|Octapharma Research Site, Durham, North Carolina, United States|Octapharma Research Site, Cincinnati, Ohio, United States",https://ClinicalTrials.gov/show/NCT01938378
Completed,Osteoporosis,Drug: Zoledronic Acid,Aarhus University Hospital|University of Aarhus|Amgen,61,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,13-Mar-17,14-Jan-21,"Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark, Aarhus, Denmark",https://ClinicalTrials.gov/show/NCT03087851
Completed,Kidney Transplantation,Procedure: Kidney Biopsy|Drug: Rapamune (sirolimus/rapamycin)|Drug: Tacrolimus,University at Buffalo|Novartis|University of Washington,58,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Jan-08,1-Dec-20,"Buffalo General Hospital Multi-Organ Transplant Department, Buffalo, New York, United States",https://ClinicalTrials.gov/show/NCT00896012
Completed,Postoperative Pain Following Knee Arthroplasty,Drug: Active comparator: Control: Femoral perineural local anesthetic infusion|Drug: Experimental: Adductor Canal perineural local anesthetic infusion,"University of California, San Diego|Summit Medical Products, Inc.|Teleflex",80,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Dec-12,17-Feb-20,"University of California San Diego Medical Centers, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT01759277
Completed,Schizophrenia|Metabolic Syndrome X|Insulin Resistance,Drug: Switch|Drug: Control,Veterans Medical Research Foundation|National Institute of Mental Health (NIMH)|Pfizer,77,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Jun-06,21-Aug-20,"VA San Diego Healthcare System, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT00338949
Completed,Pediatric HIV|HIV Infections,Drug: Boosted Atazanavir,Phoenix Children's Hospital|Bristol-Myers Squibb,10,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,26-Aug-09,20-Apr-20,"Phoenix Children's Hospital, Phoenix, Arizona, United States",https://ClinicalTrials.gov/show/NCT00940771
Completed,Chronic Hepatitis C,Drug: sofosbuvir/ledipasvir|Drug: ombitasvir/paritaprevir/ritonavir (Phase 1 only)|Drug: elbasvir/grazoprevir|Drug: Dasabuvir|Drug: Ribavirin,University of Florida|Patient-Centered Outcomes Research Institute|Merck Sharp & Dohme Corp.|AbbVie,1275,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Jun-16,24-Nov-20,"Liver Wellness Center, Little Rock, Arkansas, United States|Stanford University, Palo Alto, California, United States|UCSD Medical Center, San Diego, California, United States|UCSF/Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, United States|Univ of California, San Francisco, San Francisco, California, United States|Yale University Digestive Diseases, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|University of Florida, Jacksonville, Jacksonville, Florida, United States|University of Miami/Schiff Center for Liver Diseases, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Internal Medicine Associates of Wellstar Atlanta Medical Center, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|John Hopkins University, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|GI Associates & Endoscopy Center, Flowood, Mississippi, United States|Saint Louis University, Saint Louis, Missouri, United States|University of Nebraska Medical Ctr, Omaha, Nebraska, United States|Southwest CARE Center, Santa Fe, New Mexico, United States|Mt. Sinai Beth Israel, New York, New York, United States|New York Langone Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Mountain View Medical Center, Valatie, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Research Specialist of Texas, Houston, Texas, United States|Bon Secours St. Mary 's Hospital of Richmond (Liver Institute of Virginia), Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT02786537
Completed,Schizophrenia,"Behavioral: Cognitive remediation training (CT)|Behavioral: Healthy behavior training (HBT)|Drug: Risperidone, administered orally (Oral Ris)|Drug: Risperidone, administered via injection (RLAI)","University of California, Los Angeles|National Institute of Mental Health (NIMH)|Janssen Scientific Affairs, LLC",92,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Mar-06,26-Mar-20,"Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT00333177
Completed,Schizophrenia,Drug: Oral Risperidone|Drug: Risperidone in Long-Acting Injectable Form (Consta),"University of California, Los Angeles|National Institute of Mental Health (NIMH)|Janssen Scientific Affairs, LLC",126,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Mar-06,23-Mar-20,"Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT00330551
Completed,HIV|HIV Infections,"Drug: Raltegravir, tenofovir/emtricitabine","University of California, San Francisco|California HIV/AIDS Research Program|Gilead Sciences|Merck Sharp & Dohme Corp.",16,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Dec-09,1-Jul-20,"San Francisco General Hospital, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT01025427
Completed,Breast Cancer,Drug: 3D HI and SHI of UCA,"Thomas Jefferson University|National Cancer Institute (NCI)|Lantheus Medical Imaging|University of California, San Diego",219,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Nov-11,13-Jan-20,"University of California, San Diego, La Jolla, California, United States|Thomas Jefferson University, Dept of Radiology, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT01490892
Completed,Opioid-Related Disorders,Drug: Naltrexone for extended-release injectable suspension|Drug: Oral naltrexone,"Duke University|Laura and John Arnold Foundation|Alkermes, Inc.|FHR (Fellowship Health Resources, Inc.)|Drug Treatment Court (Wake County, NC)",14,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,21-Sep-17,16-Jun-20,"Fellowship Health Resources (FHR), Raleigh, North Carolina, United States",https://ClinicalTrials.gov/show/NCT02978417
Completed,HIV Infections,Drug: Maraviroc,"University of California, San Diego|University of California, Los Angeles|University of Southern California|Pfizer|California HIV/AIDS Research Program",32,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-Oct-08,19-Aug-20,"University Southern California, Los Angeles, California, United States|University California San Diego, San Diego, California, United States|Harbor-UCLA, Torrance, California, United States",https://ClinicalTrials.gov/show/NCT00925756
Completed,Patient Adherence,Drug: Vitamin D Supplement,"University of California, San Diego|University of Southern California|University of California, Los Angeles|City of Long Beach Department of Health and Human Services|California HIV/AIDS Research Program|Gilead Sciences",48,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,15-Dec-14,2-Jul-20,"University Southern California, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States",https://ClinicalTrials.gov/show/NCT02367599
Completed,Patient Adherence|HIV Seronegativity,Device: SoC + iTab,"University of California, San Diego|University of California, Los Angeles|University of Southern California|City of Long Beach Department of Health and Human Services|California HIV/AIDS Research Program|Gilead Sciences",398,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-Dec-12,2-Jun-20,"City of Long Beach Department of Health and Human Services, Long Beach, California, United States|University Southern California, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States",https://ClinicalTrials.gov/show/NCT01761643
Completed,"Adherence, Medication|Risk Behavior|Pre-Exposure Prophylaxis|HIV Prevention",Drug: Emtricitabine / Tenofovir Disoproxil Oral Tablet|Other: DOT Diary mobile app,"Public Health Foundation Enterprises, Inc.|National Institute of Mental Health (NIMH)|San Francisco Department of Public Health|Emory University|AiCure|National Institute of Allergy and Infectious Diseases (NIAID)",20,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,28-Feb-18,19-Feb-20,"Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States|Emory University, School of Public Health, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT03387462